



NATIONAL HEALTH FUND

HEAD OFFICE: 6TH Floor, The Towers, 25 Dominica Drive, Kingston 5
Tel: (876) 906-1106 Fax: 906-1105 Toll-free 1-888-643-2273 Website:
www.nhf.org.jm

PHARMACEUTICAL DIVISION: Tel. (876) 923-6920/923-6926-8 Fax. 923-7159

April 27, 2011

Dear Sirs:

The National Health Fund, which now has responsibility for the procurement, warehousing and distribution of pharmaceuticals and medical supplies, previously carried out by **Health Corporation Limited** on behalf of the government of Jamaica, is inviting tenders for **pharmaceutical preparations**. The Schedule of Requirements include pharmaceutical items for use in the **government's health facilities** and in the **Jamaica Drug for the Elderly Programme (JADEP)**, and is for a **24-month** contract period, effective November 1, 2011 to October 31, 2013. Enclosed are the following documents:

- Instructions to Bidders
- Tender Form
- General Conditions of Contract
- Special Conditions of Contract
- Schedule of Requirements
- Payment Form
- Registration Form

If you are interested in tendering, kindly complete and submit the following:

- Tender Form
- Copy of valid Tax Compliance Certificate (local bidders)
- Copy of valid National Contracts Commission certification in the category of 'Medical, Pharmaceutical Equipment and Supplies' (local bidders)
- Bid security of J\$150,000 or the equivalent in United States dollars, in the form of a manager's cheque payable to The National Health Fund, or a banker's guarantee
- Schedule of Requirements
- Payment Form
- Testimonials (where applicable)

Failure to submit your signed and stamped/sealed Tender Form will result in your tender being deemed non-responsive. Overseas bidders are required to submit proof of registration with the National Contracts Commission prior to award of contracts and are invited to visit the NCC website at www.ncc.gov.jm for registration instructions.

.../2



NATIONAL HEALTH FUND

HEAD OFFICE: 6TH Floor, The Towers, 25 Dominica Drive, Kingston 5
Tel: (876) 906-1106 Fax: 906-1105 Toll-free 1-888-643-2273 Website:
www.nhf.org.jm

PHARMACEUTICAL DIVISION: Tel. (876) 923-6920/923-6926-8 Fax. 923-7159

All required documents must be returned to The National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, no later than **2:00 p.m. on Friday, June 3, 2011**. Bids will be opened at **2:05 p.m. on Friday, June 3, 2011**, in the Conference Room at The National Health Fund, in the presence of bidders' representatives who choose to attend.

Awards will only be made for those pharmaceutical preparations which are duly registered in accordance with the Food and Drug Act (1964) of the Laws of Jamaica. Applications for registration may be sent to the Ministry of Health, Oceana Complex, 2-4 King Street, Kingston, Jamaica, West Indies. It is suggested that registration be pursued well in advance of the tendering process, as the registration process takes approximately three to six months.

Your attention is drawn to the following paragraphs of the enclosed Instructions To Bidders:

- Paragraph 5.6. which states that tenders received after the deadline specified at Paragraph 5.1. will be rejected and returned unopened.
- Paragraph 9.2.1. which states that a copy of the Pharmaceutical Product Licence, issued by the Ministry of Health, or a list of the product licence registration number, must be submitted for all products tendered.
- Paragraph 9.2.1. which states that tenderers must provide samples, in the package size being tendered, for any pharmaceutical preparation, not previously supplied to HCL, now The National Health Fund, Pharmaceutical Division.

New tenderers must furnish testimonials and evidence of the financial strength of the company. The testimonials should be from **at least two** institutions with whom the tenderer has successfully executed contracts for similar products and should indicate the tenderers prior experience and ability to perform.

Please note that all quotations must be made on a "C.I.F." basis (i.e. prices quoted must be inclusive of cost, insurance and freight).

Queries should be directed to Marcia Chin-See at mchinsee@nhf.org.jm and copied to Kirk McKain at kmckain@nhf.org.jm

Yours faithfully

Hugh Lawson (Mr.)
Chief Executive Officer

HL/mm
Encs.



INVITATION FOR BIDS

PROCUREMENT OF PHARMACEUTICAL PREPARATIONS

The National Health Fund now invites sealed bids from eligible bidders for the supply of these products as listed in the Schedule of Requirements of the tender documents, for the 24-month contract period, November 1, 2011 to October 31, 2013, for use in the government's health facilities and for the Jamaica Drug for the Elderly Programme (JADEP).

Eligibility:

For tenders to be considered, local bidders **must** be in possession of a valid Tax Compliance Certificate (TCC) and National Contracts Commission (NCC) certification in the category of 'Medical, Pharmaceutical Equipment and Supplies', copies of which must be submitted with bid proposals. Overseas bidders are required to submit proof of registration with the NCC prior to award of contracts and are invited to visit the NCC website at www.ncc.gov.jm for registration instructions.

Bids must be accompanied by a bid security of one hundred and fifty thousand Jamaican dollars (J\$150,000.00) or the USD equivalent in the form of a manager's cheque payable to National Health Fund, or a banker's guarantee.

Failure to comply with the above will result in rejection of the tender.

Collection of Documents:

Tender documents will be available at a non-refundable cost of US\$50.00 or the equivalent in Jamaican dollars payable in cash, or manager's cheque, from the receptionist, National Health Fund Office, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, from **Wednesday, April 27, 2011 between 9:00 a.m. and 4:00 p.m.**

Tender documents may be inspected at the offices of The National Health Fund or at www.nhf.org.jm. Tenders will not be evaluated unless payment for tender documents is received.

Queries:

Queries should be directed to Marcia Chin-See at mchinsee@nhf.org.jm and copied to Kirk McKain at kmckain@nhf.org.jm.

Bid Submission:

Bids along with the documents for eligibility must be delivered to The National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, in a sealed envelope and placed in the tender box marked "Tender for Pharmaceutical Preparations", located in the foyer, **no later than 2:00 p.m., Friday, June 3, 2011**. Proposals should be addressed as set out below:

**Tender – Procurement of Pharmaceutical Preparations
The National Health Fund
6th Floor, The Towers
25 Dominica Drive
Kingston 5
Jamaica W.I.**

Tender Opening:

Tenders will be publicly opened at **2:05 p.m., Friday, June 3, 2011** in the Conference Room of The National Health Fund. Bidders and/or their representative are invited to attend.

The National Health Fund will not be held responsible for bid(s) not received on or before the time and date specified for receipt of bid(s). **Late bid(s) will be rejected and returned to the bidder unopened.**



**MINISTRY OF HEALTH
STANDARDS & REGULATION DIVISION
PHARMACEUTICAL & REGULATORY AFFAIRS DEPARTMENT
JAMAICA, WEST INDIES
REGISTRATION OF NEW DRUGS
FOOD AND DRUGS ACT 1964**

Product Particulars:

1. NAME OF DRUG:

.....

2. GENERIC NAME OR NON-PROPRIETARY DESIGNATION OF DRUG:

.....

3. NAME AND ADDRESS OF MANUFACTURER:.....

.....

4. NAME AND ADDRESS OF APPLICANT:.....

.....

5. NAME & ADDRESS OF LOCAL REPRESENTATIVE (If different from above): -

.....

LIST OF REQUIREMENTS FOR ASSESSMENT PURPOSES:

1. Three copies of a summarized statement (not package insert) giving the information on:
 - a. All ingredients present in the formulation;
 - b. Dose, Dose Schedule, Route of administration;
 - c. Therapeutic/diagnostic claims;
 - d. Description of dosage form being registered;
 - e. Contraindication/precautions;
 - f. Side effects;
 - g. Toxic effects, and protocol for treating toxicity or where applicable, antidote.
2. Details of the tests conducted to control the potency, purity, and stability.
3. Summary of:
 - a. Clinical Pharmacology: pharmacodynamics; pharmacokinetics;

- bioavailability;. Bioequivalence studies including not less than twelve (12) subjects for all generic preparations.
- b. Efficacy: controlled studies; uncontrolled studies;
 - c. Safety: adverse drug reactions in volunteers and where a new chemical moiety has been marketed for less than five (5) years, adverse drug reactions in patients.
4. A Certificate of Analysis (original, not photocopy) or a certified report containing: -
 - a. Assay report on a recent batch of the product analysed;
 - b. The method of analysis used.
 5. Five (5) copies of a draft of every label bearing the address of the **manufacturer** proposed to be used in connection with the product, a batch/lot number and expiry date of the product.
 6. Five (5) samples of the new drug in the finished pharmaceutical form in which it is to be sold along with adequate amounts of appropriate chemical and/ or biological reference standards of active ingredients necessary to perform analyses described in three (b).
 7. A “**Certificate of a Pharmaceutical Product**” (original, not photocopy) bearing information as recommended by W.H.O. from the competent health authority in the country of manufacturer certifying that the drug is approved for use and registered in that country and the conditions under which it may be sold in that country.
 8. A statement showing:
 - a. The countries in which the product is approved for sale other than the country in which it is manufactured.
 - b. Any country in which the product has been refused registration and the reasons for refusal.
 9. Any other relevant information.
 10. Official documents such as the Certificates of Pharmaceutical Product should be authenticated by the Jamaican Embassy or Jamaican Consulate in the country, and in cases where none of these is present by the British High Commission or British Embassy.
 11. The document submitted **must** be in the English Language or authenticated translation should be bound in a hard cover with dimensions of approximately 9” x 11 ½ “ and correctly indexed in the order presented above for easy reference.
 12. The registration fee for each presentation is five thousand dollars (J\$5,000.00). Cheques **must** be made payable to the Permanent Secretary, Ministry of Health.
 13. All the above requirements must be submitted at the same time to the **PHARMACEUTICAL & REGULATORY AFFAIRS DEPARTMENT. Incomplete submissions will be returned to the applicant.**

Note: GENERIC COMPANIES ARE REQUIRED TO INDICATE THE EXPIRY DATE OF THE PATENT ON THE PRODUCT BEING SUBMITTED FOR REGISTRATION.

ACCEPTANCE OF REGISTRATION DOCUMENTS BY THE MINISTRY OF HEALTH IS NOT AN INDICATION THAT REGISTRATION IS AUTOMATIC.

WITH THE EXCEPTION OF PRODUCTS INDICATED FOR LIFE THREATENING ILLNESSES (e.g. HIV, CANCER), PRODUCTS SUBMITTED FOR REGISTRATION SHOULD BE ON THE MARKET IN THE COUNTRY OF MANUFACTURE OR EXPORT FOR AT LEAST ONE (1) YEAR PRIOR TO SUBMISSION.

FOR CONSIDERATION OF APPROVAL IN JAMAICA WHERE AN INNOVATOR DRUG IS NOT REGISTERED IN JAMAICA ANY GENERIC FORM SUBMITTED FOR APPROVAL WILL BE CONSIDERED A NEW DRUG. THE LIST OF REQUIREMENTS FOR A NEW DRUG WILL THEREFORE APPLY.

CONDITIONS OF REGISTRATION: -

- LIST 4 Prescription Only**
- LIST 2 Over-the-Counter LIST 2 Drug by the Pharmacy Council of Jamaica and may be sold in Pharmacies ONLY**
- LIST 1 Over-the-Counter LIST 1 Drug by the Pharmacy Council of Jamaica and may be sold in shops other than Pharmacies**

FOR OFFICE USE ONLY

DATE RECEIVED:.....

NOTIFICATION SENT:.....

ASSESSMENT COMMENTS:.....

DATE APPROVED/REFUSED:.....

M.H.F.D. 13 Revised May 2006.

INSTRUCTIONS TO BIDDERS FOR PROCUREMENT OF PHARMACEUTICAL PREPARATIONS

to be supplied and delivered to

THE NATIONAL HEALTH FUND

A company incorporated under the Laws of Jamaica, with registered offices at the 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, Jamaica and hereinafter referred to as the 'Company'.

1. GENERAL

The National Health Fund, (NHF) was established by an ACT of Parliament in 2003, to provide financial support to the national healthcare system in order to improve its effectiveness and by extension, the health of the Jamaican population.

Effective March 31, 2011, the Government of Jamaica took the decision to cease the operations of Health Corporation Limited (HCL) and that the NHF assume the functions previously performed by HCL. The NHF ACT was amended on March 8, 2011 to facilitate these changes.

The NHF Pharmaceutical Division located at 78 Marcus Garvey Drive, Kingston 13, has responsibilities for the procurement, warehousing and distribution of pharmaceuticals and medical supplies for the state-owned hospitals and health centers. The NHF also assumed the management of the DrugServ pharmacies, which dispense medications for the government's Abolition of User Fee programme, and also provide competitively priced pharmaceuticals to the Jamaican public, through prescriptions originating from non-government health facilities or private healthcare providers.

2. ELIGIBILITY

To be considered eligible for participation in this tender, bids at the time of opening, must include the following:

- (a) A signed and stamped/sealed Tender Form
- (b) Bid security of J\$150,000.00 or the equivalent in United States dollars, in the form of a manager's cheque payable to The National Health Fund, or a banker's guarantee
- (c) Copy of valid Tax Compliance Certificate (local bidders)
- (d) Copy of valid National Contracts Commission (NCC) certification in the category of 'Medical, Pharmaceutical Equipment and Supplies' (local bidders)
- (e) Testimonials (where applicable)

Failure to submit your signed and stamped/sealed Tender Form will result in your tender deemed non-responsive. Overseas bidders are required to submit proof of registration with the NCC prior to award of contracts and are invited to visit the NCC website at www.ncc.gov.jm for registration instructions.

3. COLLECTION OF BID DOCUMENTS

- 3.1 A complete set of bid documents, in English, is available for purchase as of Wednesday, April 27, 2011 between the hours of 9:00 a.m. and 4:00 p.m., for a non-refundable fee of US\$50.00 or its Jamaican dollar equivalent. Payment must be made by cash, manager's cheque or wire transfer and made payable to The National Health Fund.
- 3.2 Prospective bidders must first pay at the Cashier's booth at the National Health Fund, and on presentation of the receipt, the holder will be able to collect bid documents at the Receptionist's desk of the said company, after signing the Tender Documents Issued Register. The Bidder or his representative must ensure that clear contact details are entered in the Register.

4. PREPARATION OF TENDERS

- 4.1 The tender prepared by the tenderer shall be comprised of the following components:
- (a) A completed and signed, stamped or sealed Tender Form
 - (b) A Schedule of Requirements completed in accordance with Sections 4.2. – 4.13. below
 - (c) Payment Form
 - (d) Testimonials (where applicable)
 - (f) Bid security of J\$150,000.00 or the equivalent in United States dollars, in the form of a manager's cheque payable to The National Health Fund, or a banker's guarantee
 - (e) Copy of valid Tax Compliance Certificate (local bidders)
 - (f) Copy of valid National Contracts Commission certification in the category of 'Medical, Pharmaceutical Equipment and Supplies (local bidders)
 - (g) A copy of the Pharmaceutical Product Licence issued by the Ministry of Health or a list of the product licence registration number for all items for which bids are submitted. Samples **must** also be submitted, in the package size being tendered, for any item not previously supplied to Health Corporation Limited, now The National Health Fund.
- 4.2 Overseas suppliers shall indicate on the Schedule of Requirements the price per stated unit, inclusive of the cost of insurance and freight to the port-of-entry in Kingston, Jamaica, and the extensions against the individual items it proposes to supply under the contract.
- 4.3 Locally based tenderers shall insert the ex-factory/ex-warehouse price per stated unit, including all custom duties, sales and other taxes already paid, and all other costs incurred in making delivery of the contracted supplies to the company's warehouse.
- 4.4 The **total value** of the tenderer's proposed bid price must be stated on both the final page of the Schedule of Requirements and on the Tender Form.
- 4.5 For selected items, the Company guarantees to purchase at least fifty percent of the estimated quantities set out in the Schedule of Requirements. These items are marked by two asterisks on the Schedule of Requirements. The quantities of all other items are estimated quantities and are only given as a guide to tenderers.
- 4.6 The tender price shall be quoted in U.S. currency and must be fixed for both the period of tender validity prescribed in Section 7 and during the tenderer's performance of the Contract. A tender submitted with an adjustable price quotation will be treated as non-responsive and rejected.
- 4.7 Discounts, if any, should be stated in the Remarks column of the Schedule of Requirements and should not be reflected in any total prices inserted.
- 4.8 The tenderer shall indicate **clearly** any deviation from the description or package size stated on the Schedule of Requirements; the Brand/Trade/Labelled name of the product, and if not the tenderer's product, **the name of its manufacturer**.
- 4.9 The tenderer shall indicate by writing "**NOT APPLICABLE**" (N.A.) in the column "Unit Cost Air" against those items which cannot be air freighted e.g. inflammable items.

- 4.10 The tenderer **must** indicate clearly beside each item for which a bid is submitted the expected lead time for the specific item. **Failure to indicate the lead time for any item will result in the item not being evaluated.**
- 4.11 Erasures or other changes must be explained or otherwise noted over the signature or initials of the person or persons signing the tender.
- 4.12 The tender form shall be signed by the tenderer or person or persons duly authorized to bind the tenderer to the Contract. **All** pages of the tender shall be initialed by the person or persons signing the tender.
- 4.13 Tenderers must provide samples, in the package size being tendered, for any pharmaceutical preparation not previously purchased by HCL, now The National Health Fund. The Company reserves the right to demand samples of any other product for which the tenderer has submitted a bid. Failure to provide such samples upon demand may result in rejection of the bid.

5 TENDER SUBMISSION

- 5.1 Tenderers must submit their tender proposal in an envelope, which should be clearly marked "**TENDER – PROCUREMENT OF PHARMACEUTICAL PREPARATIONS**" and addressed to: The National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, Jamaica, in accordance with the instructions given in Subsection 5.2 below. Tender documents should arrive at or before **2:00 p.m. on Friday, June 3, 2011**, and placed in the tender box labeled "**Tender – Pharmaceutical Preparations**" in the foyer area of The National Health Fund.
- 5.2 Bid documents should be submitted in three envelopes, which should be properly sealed to prevent any possibility of undetected tampering. The outer envelope marked '**TENDER – PROCUREMENT OF PHARMACEUTICAL PREPARATIONS**' should contain separate inner envelopes marked, (i) the **Documents for Eligibility** for documents stated in Section 2 above, and (ii) the **Tender Proposal**, which includes the Schedule of Requirements and completed Payment Form. Both these envelopes are to be inserted in the outer envelope marked '**TENDER – PROCUREMENT OF PHARMACEUTICAL PREPARATIONS**'. Failure to submit the required documents will result in the bid being deemed non-responsive.
- 5.3 The Tender Receival Register located at the Receptionist's Desk at NHF shall be signed by all bidders or their representatives and witnessed by a representative of NHF upon submission of bid documents.
- 5.4 After signing the Tender Receival Register, all bid submissions should be dropped in the Tender Box marked "**Tender – Pharmaceutical Preparations**" located in the foyer area of The National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5, no later than **2:00 p.m. on Friday, June 3, 2011**.
- 5.5 The bidder or its representative is responsible for placing the bid submission in the correct Tender Box.
- 5.6 Tenders received after the deadline specified in Subsection 5.1 will be rejected and returned to the bidder or its representative unopened.**
- 5.7 If the tenderer fails to comply with Subsection 5.2. above, the Company will assume no responsibility for the misplacement or premature opening of the tender.
- 5.8 Quotations submitted to the Company by telephone, facsimile or e-mail will not be accepted.

- 5.9 Local bidders must submit copies of their valid Tax Compliance Certificate and National Contracts Commission certification. Overseas bidders must submit proof of registration with the NCC prior to award of contracts.
- 5.10 Tenders will not be evaluated unless payment for tender documents is received.

6 PUBLIC OPENING

- 6.1 The public opening of tenders for the Procurement of Pharmaceutical Preparations will take place on **Friday, June 3, 2011 at 2:05 p.m.** in the Conference Room at National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5.
- 6.2 All bidders or their representatives are invited to attend the Public Opening.
- 6.3 Upon opening the envelope marked **Documents for Eligibility**, the documentation will be examined carefully for the items stated under Section 2 “**ELIGIBILITY**”. Upon acceptance of the proposal, the bidder or its representative and members of the NHF Procurement Committee who are present at the Public Opening, shall sign the documents received and in particular the Tender Opening Form.

7 PERIOD OF TENDER VALIDITY

- 7.1 Tenders shall remain valid for not less than **one hundred and eighty (180) days** after the deadline for the submission of tenders prescribed in Subsection 5.1. above. A tender valid for a shorter period will be rejected by the Company as non-responsive.

8 MODIFICATION AND WITHDRAWAL OF TENDERS

- 8.1 The tenderer may modify or withdraw his tender after submission, provided that a written notice of the modification or withdrawal is received by the Company prior to the deadline prescribed in Subsection 5.1. above. The written notice should be addressed to: The National Health Fund, 6th Floor, The Towers, 25 Dominica Drive, Kingston 5. All modifications shall be submitted in accordance with Subsection 5.1 above, and labeled ‘**Modified Tender Documents**’.
- 8.2 No tender may be modified subsequent to the deadline for the submission of tenders.

9 EVALUATION OF TENDERS

- 9.1 The Company does not bind itself to accept the lowest price for any tender. It will be influenced by the information supplied by the tenderer, particularly by those concerning lead times, past performance and payment terms.
- 9.2 Tenders will be evaluated on an item-by-item basis using the following criteria:

9.2.1 Registration

A supplier’s registration status will determine whether or not his bid will be eligible for evaluation. If the following stipulations are not met, the bid will be deemed non-responsive:

Pharmaceutical preparations must be registered in accordance with the Food and Drug Act (1964) of the Laws of Jamaica as verified by the Ministry of Health Standards and Regulatory Affairs Department.

A copy of the Pharmaceutical Product Licence issued by the Ministry of Health or a list of the product licence registration number for all items for which

bids are submitted must be included with the tender submission. The tenderer **must** also submit samples, in the package size being tendered, for any pharmaceutical preparation, not previously supplied to HCL, now The National Health Fund, Pharmaceutical Division.

9.2.2 Price

The proposed prices will be ranked in ascending order to indicate the supplier(s) with the lowest price for a particular item.

For the most part, items will be awarded to a single supplier except where two suppliers have submitted the same bid price. In such cases, the award will be shared equally.

Additionally, shared awards for vital items may be made for the following reasons:

- A vital item with the lowest bid from a first time bidder
- A vital item where past performance of the lowest bidder was inconsistent
- A vital item where dependency on a sole supplier is not recommended

The shared awards of the vital items will be calculated, and awarded in accordance with the following proportions, based on the price differentials:

<u>Price differential</u>	<u>Share proportion (lower:higher)</u>
0 – 19%	50:50
20 – 39%	60:40
40 – 59%	70:30
60% and above	80:20

For the purposes of this clause, vital items are those marked by a single asterisk on the Schedule of Requirements. Vital items are classified as drugs that are potentially life saving or which are considered the drug of choice or ‘first line’ items in their respective therapeutic category.

When comparing bids, an estimated percentage for custom duty, finance charges and clearance costs will be applied, where applicable.

9.2.3 Lead time

Preference will be shown to the supplier with the lowest delivery lead time proposed on the Schedule of Requirements.

For lead times offered by the tenderer, a percentage increase, as outlined below, will be applied to the bid price:

≤ 4 weeks	0%
> 4 and ≤ 6 weeks	2%
> 6 and ≤ 8 weeks	3%
> 8 and ≤ 10 weeks	4%
>10 and ≤ 12 weeks	5%
Over 12 weeks.....	6%

Symbol	Meaning
≤	Less than or equal to
≥	Greater than or equal to
>	Greater than

9.1.4 Payment Terms

Based on the information supplied on the Payment Form, a percentage increase will be applied to the bid price, where relevant, as stated below:

A 2% increase to offset finance charges associated with Sight Draft payment method.

For Open Account, the percentage increase is as follows:

30 days	2%
60 days	1.5%
90 days	1%
120 days.....	0.5%
180 days	0.25%
240 days	0%

9.2.5 Past Performance

In the case of suppliers awarded contracts on previous pharmaceutical tenders, the supplier's ranking as assessed in the Supplier Performance Ranking System (SPRS) will be used to determine past performance criteria for evaluation.

In the case where a supplier is bidding for the first time, the Company may consider a shared award where the price may be less than or equal to that of a supplier with an outstanding performance based on the SPRS.

10 TESTIMONIALS

- 10.1 All suppliers, not previously awarded contracts for the supply of pharmaceutical preparations, shall furnish testimonials or evidence in such forms as the Company may indicate and deem necessary to the evaluation process, as to its financial ability, prior experience and ability to perform. The testimonials should be from **at least two** institutions with whom the tenderer has successfully executed contracts for similar products and should indicate the tenderers' prior experience and ability to perform. No contract will be entered into with a tenderer failing to submit such testimonials on request or submitting testimonials deemed by the Company to be inadequate.

11 CORRECTION OF ERRORS

- 11.1 Arithmetical errors will be rectified on the following basis:
- If there is a discrepancy between the unit price and the total price, the unit price shall prevail and the total price shall be corrected.
 - If there is a discrepancy between subtotals and total price, the subtotals shall prevail and the total price corrected.
 - If there is a discrepancy between words and figures, the amount in words will prevail. If a Bidder does not accept the correction of errors, his bid will be rejected.

12 CLARIFICATION OF TENDERS

- 12.1 Tenderers seeking clarification on any matter relating to the tender exercise must submit same in writing prior to the deadline for submission of tenders. The written query should be addressed to The Director, Supply Chain, National Health Fund Pharmaceutical Division, 78 Marcus Garvey Drive, Kingston 13, Fax # 923-

9593 or e-mail mchinsee@nhf.org.jm and copied to kmckain@nhf.org.jm no later than Friday, May 27, 2011. All queries and responses to same shall be duly communicated to all prospective tenderers on the Documents Issued Register, having purchased tender documents.

- 12.2 To assist in the evaluation of tenders the Company may, at its discretion, ask the tenderer for a clarification of its tender. The request for clarification and the response shall be in writing and no change in the price or substance of the tender shall be sought, offered or permitted.

13 NOTIFICATION AND ACCEPTANCE OF TENDER

- 13.1 The Company, if it accepts a tender, either in whole or in part, shall forward to the respective successful tenderers written Notice of Acceptance by e-mail or telefax, to be confirmed in writing by mail.
- 13.2 Tenderers are requested to submit copies of the relevant Material Safety Data Sheet (MSDS) for items awarded, on notification of awards.

14 CONTRACT PERIOD

- 14.1 Upon notification of acceptance, a Contract embodying the Instructions to Tenderers, the Tender Form, Schedule of Requirements, Conditions of Contract and Payment Form annexed hereto, as well as the Notice of Acceptance and Form of Agreement, shall come into existence between the parties, for a **24-month contract period**, effective from the **1st day of November, 2011** and terminate on the **31st day of October, 2013**.

15 DISCLAIMER

- 15.1 NHF and its duly appointed representatives will take no responsibility for the following:
- misrepresentation of contents of each proposal
 - clarity and accuracy of said proposal
 - mislabeling, misplacement and/or omission of any information from the proposal.
- 15.2 **The Company reserves the right to accept the whole or part of the quantity offered by the tenderer at the same unit price. It also reserves the right to reject any or all tenders or to accept any part of any tender and reject the other part.**

GENERAL CONDITIONS OF CONTRACT

1. GENERAL PROVISIONS

1.1 Definitions

Unless the context otherwise requires, the following terms whenever used in this Contract have the following meanings:

- (a) “Acceptance” means the Client’s written certification that the goods have been tested and verified as complete and in accordance with the Contract Specifications.
- (b) “Applicable Law” means the laws and any other instruments having the force of law in Jamaica, as they may be issued and in force from time to time;
- (c) “Contract” means the Contract signed by the Parties, to which these General Conditions of Contract (GC) are attached, together with all the documents listed in Clause 1 of such signed Contract;
- (d) “Contract Price” means the price to be paid for the goods, in accordance with tender documents, including any technical specifications;
- (e) “Defects Liability Period” means a period of time, as stated in the SC, during which any defects in material or workmanship shall be made good at the expense of the Contractor;
- (f) “Effective Date” means the date on which this Contract comes into force and effect pursuant to GC 2.1;
- (g) “Foreign currency” means any currency other than local currency;
- (h) “GC” means these General Conditions of Contract;
- (i) “Government” means the Government of Jamaica;
- (j) “Local currency” means Jamaican currency;
- (k) “Party” means the Client or the Contractor, as the case maybe, and “Parties” means both of them;
- (l) “Personnel” means persons hired by the Contractor as employees and assigned to the performance of the contract or any part thereof;
- (m) “Project Site” means the site for delivery of the goods and any incidental services;
- (n) “SC” means the Special Conditions of Contract by which the GC may be amended or supplemented;
- (o) “Services” means any incidental services (including transportation, installation, after-sales service, etc.) to be performed pursuant to this Contract, as shown in the SC;
- (p) “Third Party” means any person or entity other than the Government, the Client, or the Contractor.

1.2 Law Governing the Contract

This Contract, its meaning and interpretation, and the relation between the Parties shall be governed by the Applicable Law.

1.3 Language

This Contract has been executed in the English language as specified in the SC, which shall be the binding and controlling language for all matters relating to the meaning or interpretation of this Contract.

- 1.4 **Headings** The headings shall not limit, alter or affect the meaning of this Contract.
- 1.5 **Notices**
- 1.5.1 Any notice, request, or consent required or permitted to be given or made pursuant to this Contract shall be in writing. Any such notice, request or consent shall be deemed to have been made when delivered in person to an authorized representative of the Party to whom the communication is addressed, or when sent by registered mail, telex, telegram, or facsimile to such Party at the address specified in the SC.
- 1.5.2 Notice will be deemed to be effective as specified in the SC.
- 1.5.3 A party may change its address for notice hereunder by giving the other party notice of such change.
- 1.6 **Authorized Representatives** Any action required or permitted to be taken, and any document required or permitted to be executed, under this Contract by the Client or the Contractor may be taken or executed by the officials specified in the SC.
- 1.7 **Taxes and Duties** Unless otherwise specified in the SC, the Contractor shall pay such taxes, duties, fees, and other impositions as may be levied under the Applicable Law.

2. COMMENCEMENT, COMPLETION, MODIFICATION, AND TERMINATION OF CONTRACT

- 2.1 **Contract Effectiveness** This Contract shall come into force and effect on the date (the “Effective Date”) of the Parties signing the Contract.
- 2.2 **Commencement** The Contractor shall begin carrying out the provisions of Contract as specified in the SC.
- 2.3 **Expiration of Contract** Unless terminated earlier pursuant to Clause GC 2.8 hereof, this Contract shall terminate at the end of project duration, pursuant to the SC, or such other period as the parties may agree in writing.
- 2.4 **Entire Agreement** This Contract contains all covenants, stipulations and provisions agreed by the Parties. No agent or representative of either Party has authority to make, and the Parties shall not be bound by or be liable for, any statement, representation, promise or agreement not set forth herein.
- 2.5 **Modification** The Client may at any time, by a written Order given to the Contractor make changes within the general scope of the Contract for the goods to be supplied. Such changes shall not cause an increase or decrease in the Contract price.
- 2.6 **Force Majeure**
- For the purposes of this Contract, “Force Majeure” means an event which is beyond the reasonable control of a Party, and which makes a Party’s performance of its obligations hereunder impossible or so impractical as reasonably to be considered impossible in the circumstances, and includes, but is not limited to, war, riots, civil disorder, earthquake, fire, explosion, storm, flood or other adverse weather conditions, strikes, lockouts or other industrial action (except where such strikes, lockouts or other industrial action are within the power of the Party invoking Force Majeure to prevent), confiscation or any other action by government agencies.
- Force Majeure shall not include (i) any event which is caused by the negligence or intentional action of a Party or such Party’s agents or employees, nor (ii) any event which a diligent Party could reasonably have been expected to both (A) take into account at the time of the conclusion of this Contract and (B) avoid or overcome in the carrying out of its obligations hereunder.
- Force Majeure shall not include insufficiency of funds or failure to make any payment required hereunder.

- 2.6.1 **No Breach of Contract** The failure of a Party to fulfill any of its obligations hereunder shall not be considered to be a breach of, or default under, this Contract insofar as such inability arises from an event of Force Majeure, provided that the Party affected by such an event has taken all reasonable precautions, due care and reasonable alternative measures, all with the objective of carrying out the terms and conditions of this Contract.
- 2.6.2 **Measures to be reasonable Taken obligations**
- (a) A Party affected by an event of Force Majeure shall take all measures to remove such Party's inability to fulfill its obligations hereunder with a minimum of delay.
 - (b) A Party affected by an event of Force Majeure shall notify the other Party of such event as soon as possible, and in any event not later than fourteen (14) days following the occurrence of such event, providing evidence of the nature and cause of such event, and shall similarly give notice of the restoration of normal conditions as soon as possible.
 - (c) The Parties shall take all reasonable measures to minimize the consequences of any event of Force Majeure.
- 2.6.3 **Extension of Time** Any period within which a Party shall, pursuant to this Contract, complete any action or task, shall be extended for a period equal to the time during which such Party was unable to perform such action as a result of Force Majeure.
- 2.6.4 **Consultation** Not later than fourteen (14) days after the Contractor, as the result of an event of Force Majeure, has become unable to perform a material portion of the contract, the Parties shall consult with each other with a view to agreeing on appropriate measures to be taken in the circumstances.
- 2.7 **Suspension** The Client may, by written notice of suspension to the Contractor, suspend all payments to the Contractor hereunder if the Contractor fails to perform any of their obligations under this Contract, including the carrying out of the incidental services, provided that such notice of suspension (i) shall specify the nature of the failure, and (ii) shall request the Contractor to remedy such failure within a period not exceeding fourteen (14) days after receipt by the Contractor of such notice of suspension.
- 2.8 **Termination** The Client may, by not less than ten (10) days' written notice of termination to the Contractor (except in the event listed in paragraph (f) below, for which there shall be a written notice of twenty (20) days), such notice to be given after the occurrence of any of the events specified in paragraphs (a) through (f) of this Clause GC 2.8, terminate this Contract:
- (a) if the Contractor fails to remedy a failure in the performance of their obligations hereunder, within ten (10) days of receipt of such notice or within such further period as the Client may have subsequently approved in writing;
 - (b) if the Contractor becomes insolvent or bankrupt or enters into any agreements with their creditors for relief of debt or takes advantage of any law for the benefit of debtors or goes into liquidation or receivership whether compulsory or voluntary;
 - (c) if the Contractor fails to comply with any final decision reached as a result of arbitration proceedings pursuant to Clause GC 7 hereof;
 - (d) if the Contractor submits to the Client a statement which has a material effect on the rights, obligations or interests of the Client and which the Contractor knows to be false;
 - (e) if, as the result of Force Majeure, the Contractors are unable to

perform a material portion of the contract for a period of not less than sixty (60) days; or

- (f) if the Client, in its sole discretion and for any reason whatsoever, decides to terminate this Contract.

3. OBLIGATIONS OF THE CONTRACTOR

- 3.1. Standards** The goods and services supplied under this Contract shall conform to the standards detailed in the Contract Specifications. The Contractor shall carry out their obligations hereunder with all due diligence, efficiency, and economy, in accordance with the contract documents, and shall observe sound environmental practices, and employ appropriate advanced technology and safe and effective equipment, machinery, materials and methods, as necessary. The Contractor shall always act, in respect of any matter relating to this Contract, safeguard the Client's legitimate interests, pursuant to this Contract.
- 3.2 Diligence and Due Care** Contractor is responsible for, and obligated to conduct all contracted activities with due care and diligence, in accordance with the Contract and using state-of-the-art methods and exercising all reasonable means to achieve the performance specified in the Contract.
- The Contractor is responsible for managing the activities of its personnel and will hold itself responsible for any misdemeanors.
- The Contractor shall appoint an experienced Representative to manage its performance of the Contract throughout execution. The Representative shall be authorized to accept orders and notices on behalf of the Contractor, and to generate notices and commit the Contractor to specific courses of action within the scope of the Contract.
- The Contractor shall complete delivery, repairs and/or replacements in accordance with Contract requirements.
- 3.3 Contractor and Affiliates not to be Otherwise Interested in Project** The Contractor agrees that, during the term of this Contract and after its termination the Contractor and any entity affiliated with the Contractor, as well as any Subcontractor and any entity affiliated with such Subcontractor, shall be disqualified from providing advice on or otherwise contribute to the development of the Contract Specifications of the goods to be procured under this contract.
- 3.4 Prohibition of Conflicting Activities** The Contractor shall not engage, and shall cause their Personnel not to engage, either directly or indirectly, in any of the following activities:
- (a) during the term of this Contract, any business or professional activities which would conflict with the activities assigned to them under this Contract; and
 - (b) after the termination of this Contract, such other activities as may be specified in the SC.
- 3.5 Confidentiality and Property Rights** The Contractor shall not, without the Client's prior written consent, disclose the Contract, or any provision thereof, or any specification or information furnished by or on behalf of the Client in connection therewith, to any person other than a person employed by the Contractor in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only as far as necessary for purposes of such performance.
- 3.6 Liability** The Contractor's liability shall be as set forth in the SC.
- 3.7 Insurance** The Contractor shall indemnify the Client against all actions, suits, claims, demands, costs, charges and expenses arising in connection therewith on account of any injury, loss or damage resulting from negligence of the Contractor.

Without prejudices to its liability to indemnify the Client under the GC, the Contractor shall effect insurances, pursuant to the SC and at the Client's request, shall provide evidence to the Client showing that such insurance has been taken out and maintained and that the current premiums therefor have been paid.

4. CONTRACTOR PERFORMANCE

- 4.1 Assignment perform** The Contractor shall not assign, in whole or in part, its obligations to under this Contract, except with the Client's prior written consent (such consent not to be unreasonably withheld).
- 4.2 Packing** The Contractor shall provide such packing of the goods as is required to prevent their damage or deterioration during shipment and/or other transport. The Contractor shall promptly repair or replace any goods that are damaged in transit due to inadequate packing or any other related causes.
- 4.3 Incidental Services** The Contractor is required to provide any or all of the incidental services stated in the SC, and shall include the cost(s) of such in its tender price.
- 4.4 Delivery**
- 4.4.1 The Contractor shall deliver the goods to the Client at the project site on or before the expiration of the project duration as stated in the SC.
 - 4.4.2 Time of delivery is the essence of this Contract.
 - 4.4.3 If the Contractor fails to deliver all of the goods in accordance with the Contract on the delivery date, then, without prejudice to the Client's rights for breach of Contract, the Client may terminate the Contract pursuant to the GC.
 - 4.4.4 Where delivery of a quantity of the goods under this Contract is less than the agreed quantity and the Client has not exercised its rights of termination under the GC, the Client may either accept these goods and recover for the Contractor's breach, or the Client may require the Contractor promptly to deliver sufficient goods to comply with the quantity required by the Contract. The Client may exercise these rights by written notice to the Contractor.
 - 4.4.5 The Contractor shall rectify any and all defects immediately upon notification of such defects by the Client or its representative pursuant to the GC.
- 4.5 Inspection and Acceptance** The Client, or its representative, shall have the right to inspect and/or test the goods and/or services performed to confirm their conformity to the Contract Specifications and shall notify the Contractor of the identity of any representative retained for these purposes.
- Should any inspected or tested goods and/or services fail to conform to the specifications, the Client may reject the goods and/or services and notify the Contractor of such rejection in writing. The Contractor shall forthwith either replace the rejected goods and/or services or make alterations necessary to meet specification requirements free of cost to the Client.
- At the Client's discretion, inspection for acceptance shall also be performed on the replaced and/or altered goods and/or incidental services.
- Nothing in this Clause shall in any way release the Contractor from any warranty or other obligations under this Contract.
- 4.6 Contractor Warranty** The Contractor warrants that the goods supplied under the Contract are new and unused. The Contractor further warrants that all goods supplied under this Contract shall have no defect arising from design, materials or workmanship or

from any act or omission of the Contractor.

The Client shall promptly notify the Contractor in writing of any claims arising under the Contractor's warranty. Upon receipt of such notice, the Contractor shall forthwith repair or replace the defective goods or parts thereof without cost to the Client.

If the Contractor, having been notified, fails to forthwith remedy the defect(s), the Client may proceed to take such remedial action as may be necessary, at the Contractor's risk and expense and without prejudice to any other rights that the Client may have against the Contractor under the Contract.

4.7 Manufacturer's Warranty

The Contractor shall ensure that the *Manufacturer's Warranty* on goods supplied under this Contract is available to the Client, if required by the SC and in accordance with the terms and conditions therein.

5. PAYMENTS GUARANTEES AND LIABILITIES

5.1 Contract Price set

The Contract Price is as stated in the SC, a breakdown of which is as forth in the Contractor's Tender.

5.2 Currency of Payment

The currency of payment shall be as specified in the SC.

5.3 Performance Security

If required by the SC, a Performance Security, in the amount and form as specified by the SC shall be furnished by the Contractor.

The proceeds of the performance security shall be payable to the Client as compensation for any loss resulting from the Contractor's failure to complete its obligations under the Contract.

The performance security shall be valid until discharged by the Client and returned to the Contractor not later than thirty (30) days after the completion date.

5.4 Mode of Billing and Payment

Billings and payments shall be made as follows:

- (a) If specified in the SC, the Client shall cause to be paid to the Contractor an advance payment as specified in the SC, and as otherwise set forth below. The advance payment will be due after provision by the Contractor to the Client of a bank guarantee by a bank acceptable to the Client in an amount (or amounts) and in a currency (or currencies) specified in the SC, such bank guarantee (i) to remain effective until the advance payment has been fully set off as provided in the SC, and (ii) to be in the form set forth in the Appendix hereto or in such other form as the Client shall have approved in writing.
- (b) Thereafter all other payments shall be tied to Contractor performance and in accordance with any performance-based progress payments as specified in the SC.
- (c) If required by the SC, a percentage of final payment shall be withheld, and become payable at the end of the defects liability period, as stated in the SC.

5.5 Contractor Payment Requests

With the exception of 5.4 (a), none of the above payments shall become due until the Client has received a request for payment from the Contractor. Requests shall be in writing and accompanied by an invoice describing the goods delivered and/or the services performed and upon fulfillment of any other obligations stipulated in the Contract.

5.6 Interest

Any outstanding payments due to the Contractor shall attract a rate of

interest as shown in the SC.

5.7 Delays in Contractor Performance

If at any time during performance of the Contract, the Contractor should encounter conditions impeding timely delivery of the goods and services, the Contractor shall promptly notify the Client in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable, after receipt of the Contractor's notice, the Client shall evaluate the situation and may, at its discretion, extend the Contractor's time for performance, with or without liquidated damages, in which case the extension shall be ratified by the parties by amendment of the Contract.

5.8 Liquidated Damages

Subject to Clause 5.7 of the GC, if the Contractor fails to deliver any or all of the goods within the period(s) specified in the Contract, the Client shall without prejudice to its other remedies under the Contract, deduct from monies due to the Contractor liquidated damages in the amount as specified in the SC for each day of delay.

6. FAIRNESS AND GOOD FAITH

6.1 Good Faith

The Parties undertake to act in good faith with respect to each other's rights under this Contract and to adopt all reasonable measures to ensure the realization of the objectives of this Contract.

6.2 Operation of the Contract for

The Parties recognize that it is impractical in this Contract to provide every contingency which may arise during the life of the Contract, and the Parties hereby agree that it is their intention that this Contract shall operate fairly as between them, and without detriment to the interest of either of them, and that, if during the term of this Contract either Party believes that this Contract is operating unfairly, the Parties will use their best-efforts to agree on such action as may be necessary to remove the cause or causes of such unfairness, but no failure to agree on any action pursuant to this Clause shall give rise to a dispute subject to arbitration in accordance with Clause GC 7 hereof.

7. SETTLEMENT OF DISPUTES

7.1 Amicable Settlement

The Parties shall use their best efforts to settle amicably all disputes arising out of or in connection with the Contract or its interpretation.

7.2 Dispute Settlement

Any dispute between the Parties as to matters arising pursuant to this Contract which cannot be settled amicably within fifteen (15) days after receipt by one Party of the other Party's request for such amicable settlement may be submitted by either Party for settlement in accordance with the provisions specified in the SC.

SPECIAL CONDITIONS OF CONTRACT

**Number of
GC Clause**

1.1 “Goods” means the pharmaceutical preparations described in the Schedule and which form the subject matter of this Contract

1.3 The language is English.

1.5.1 The addresses are:

For the Client: National Health Fund
Pharmaceutical Division

Attention: Mrs. Marcia Chin-See

Mailing address: 78 Marcus Garvey Drive
Kingston 13
Jamaica

Email: mchinsee@nhf.org.jm

Telephone: 876-901-2979

Facsimile: 876-923-9593

For the Contractor:

Attention:

Mailing address:

Email:

Telephone:

Facsimile:

1.5.2 Notice will be deemed to be effective as follows:

- (a) in the case of personal delivery or registered mail, on delivery in person to an authorized representative;
- (b) in the case of emails, when email message has been received by the recipient. It is advisable that the sender requests and receives a confirmation response from the recipient that the said email transmission was received: and,
- (c) in the case of facsimiles, when received. It is advised that the sender notifies the receiver, by phone, of the transmission and gets confirmation that the receiver has received said fax transmission.

1.5 The Authorized Representatives are:

For the Client: Mr. Hugh Lawson
Mrs. Marcia Chin-See
Miss I. Erica McIntosh

For the Contractor: _____

2.2 The Contract Commencement date shall be _____ or such other time period as the parties may agree in writing.

2.3 The Contract Expiration date shall be _____ or such other time period as the parties may agree in writing.

2.6 Where delivery is delayed due to causes beyond the control of the Contractor, including those causes listed in the G.C 2.6 or to delay caused by a common carrier, the Contractor shall generally be allowed the number of days he was so delayed provided that he promptly notifies the Client in writing of the cause (s) of the delay. However, if the Client, after considering the causes(s) of delay determines that the delay is inconveniencing the Client by creating an emergency in Jamaica, the Client shall have the right without liability to the Contractor to effect purchases of the goods from elsewhere providing it informs the Contractor in advance.

This determination shall be binding on the Contractor and to the extent that such purchases are made, the Contractor shall be relieved of the necessity of delivering such quantities.

2.8 The Client may terminate the Contract by sixty (60) days written notice. If termination is based on the event listed in paragraph (f), ninety (90) days written notice is to be given.

Written notice given with the occurrence of the event specified in paragraph (a) shall be given where the Contractor fails to remedy a failure within sixty (60) days of receipt of such notice.

Any termination shall not discharge, vary or modify the rights and obligations of the parties which have accrued up to the date of such termination but neither party shall incur any liability to the other including but not limited to, liability for the loss of goodwill or anticipated profits, by reason of the termination of this Contract.

3.1 The Contractor shall supply pharmaceutical preparations of the description and standards as laid down by the latest edition of the British Pharmacopoeia and/or the United States Pharmacopoeia and which shall retain potency throughout the period specified by the product's expiration date at recommended ambient conditions.

The Contractor shall ensure that all supplies forming the subject matter of this Contract are registered in accordance with the Food and Drug Act 1964 of the Laws of Jamaica. (A copy of the legal requirements for registration is enclosed for the information of the Contractor).

The pharmaceutical preparations must also conform to the Laws of that country within which they were manufactured and must be accompanied by a certificate stating that they do not contravene any requirement of the Laws of that country.

If an item allocated under the Contract is withdrawn from use in the Contractor's country, for whatever reason, the Contractor shall immediately advise the Client accordingly.

The Contractor, in signing this Contract, authorizes the Client to contact the competent authority which administers good manufacturing practices and registration standards in that country, to ascertain that the Contractor has conformed with the required practices and standards. The Client is not obliged to advise the Contractor when such contact will be, or has been made.

If an item allocated under the Contract is withdrawn from use in the Contractor's country, for whatever reason, the Contractor shall immediately advise the Client accordingly.

The Contractor, in signing this Contract, authorizes the Client to contact the competent authority which administers good manufacturing practices and registration standards in that country, to ascertain that the Contractor has conformed with the required practices and standards. The Client is not obliged to advise the Contractor when such contact will be, or has been made.

3.6. Except in cases of criminal negligence or willful misconduct, the aggregate liability of the Contractor to the Client under this Contract shall not exceed the total Contract Price. This limitation of liability shall not affect the Contractor's liability, if any, for damage to Third Parties caused by the Contractor or any person or firm acting on behalf of the Contractor in carrying out the obligations under the Contract.

3.7. The risks and the coverages shall be as follows:

- (a) Insurance against loss of or damage to medical sundries purchased in whole or in part with funds provided under this contract;
- (b) The Contractor shall produce the relevant policy or policies and premium receipts dated at least 24 hours previous to commencement of the project, when required by the Client, and should the Contractor

make default in so doing, the Client may insure against any risk with respect to which the default shall have been incurred and may deduct the premiums paid from any monies due or to become due to the Contractor.

The Contractor shall indemnify the Client against all third-party claims of infringement of patent, trademark or industrial design rights arising from use of the goods or any part thereof in Jamaica.

The onus is on the tenderer to prove that a patent exists.

The Contractor shall indemnify the Client against any liability for accidental loss, bodily injury, death or damage to property caused by the use of the items supplied to the Client.

- 4.1 This Contract is indivisible and will be awarded in its entirety to one (1) Contractor. Absolutely no subcontracting will be allowed by the selected firm under the awarded contract.
- 4.2 Goods must be packed in immediate and external export containers, suitable to withstand rough handling in transit and storage under Jamaican ambient conditions. Containers should be shrink-wrapped and sealed in a manner which makes tampering with the package during transit easily detectable. The Contractor shall be liable for all loss, damage, or expense due to insufficient or unsuitable packing.
- 4.4 The project duration is for **twelve (18) months**.

The Contractor shall deliver the goods to the Client up to two (2) months after the expiration of the project.

The Client binds itself to order at least fifty percent of those items marked by two asterisks on the Schedule of Requirements. The Client however does not bind itself to order the estimated quantities of the other items not marked by two asterisks, but reserves to itself the right to order only such quantities as it may from time to time require during the Contract period. The Client, when ordering, shall endeavour to indicate to the Contractor, where possible, a schedule of delivery in order to ensure continuity of supplies.

The Contractor shall not proceed with delivery until a Purchase Order, signed by an authorized officer, is received from the Client. On receipt of a Purchase Order, the Contractor shall issue a Purchase Order Acknowledgement to the Client, stating the expected time of arrival of the supplies.

The Contractor will, at its own expense, deliver to the Client the supplies ordered from time to time by the Client within the time stipulated by the Contractor in its tender or such earlier time as may be agreed between the Client and the Contractor. During the period of the Contract the Contractor shall deliver supplies of the stipulated description and at the prices quoted by the Contractor in its tender in such quantities as may be required by the Client. But should the delivery of supplies, according to any order given before expiration of the contract period be incomplete at the expiration of the contract period, the Contractor shall still be responsible to complete delivery of that order unless the Client indicates otherwise.

In the case of goods delivered by the Contractor not being of the stipulated description and/or quantity, the Client shall have absolute power to reject those items not meeting the description and to purchase others elsewhere without any liability to the Contractor. Any excess cost and charges incidental to such purchases shall be recoverable from the Contractor. Alternatively, the Client may request, and the Contractor shall deliver, supplies of the correct description and/or quantity to replace those items which do not meet the stipulated description and/or quantity.

Dated Products

The supplies, when received by the Client, shall not be more than one (1) year beyond the date of manufacture or not less than eighteen (18) months from the date of expiration, whichever results in the greater shelf life. In the event that the supplies can in no circumstances have a shelf life of eighteen months or more the Contractor is obliged to inform the Client in writing, in advance of delivery of these supplies, of their shelf life so that the Client can exercise its right to accept or refuse these supplies.

Where an expiration date is stated only in terms of the month and the year, it will be interpreted, unless otherwise stated by the Contractor, that the expiration date is the last day of the stated month. For articles requiring reconstitution prior to use, a suitable beyond-use date for the reconstituted product shall be identified in the labeling.

The Contractor shall replace or apply credit against outstanding invoices for payments for all those supplies which reach their expiry date within eighteen months of delivery unless the Client was previously advised by the Contractor, in writing, in advance of the delivery, that the supplies would expire within eighteen months of

delivery and the Client still consented to the delivery of such supplies. Failure to comply gives the Client the right to set off outstanding credits against amounts owed to the Contractor. Where no prior consent was given by the Client, the Contractor shall compensate the Client for all costs incurred in the disposal of expired supplies.

In cases where the Contractor wishes to supply short dated products and the Client gives conditional consent for delivery of such supplies, such agreement shall be in writing and such conditions must be complied with.

Labels

Labels, which shall not be other than manufacturer's originals, package inserts and other descriptive material shall be in the English language, in addition to any other language.

All supplies delivered must state clearly on the label the storage conditions required to ensure maximum potency of the active ingredients at time of use. For articles requiring reconstitution prior to use suitable storage conditions following reconstitution shall be indicated in the labeling.

Any expense involved in re-labeling external or internal containers will be met by the Contractor. Supplies not properly labeled may be returned to the Contractor at its expense.

Delivery Documents

All supplies should be consigned to the Client exclusively.

For imported supplies, upon shipment, the Contractor shall notify the Client and the Insurance Company by e-mail or telefax the full details of the shipment including description of supplies, quantity, the name of the vessel, the bill of lading or air waybill number and date, port of loading, date of shipment, port of discharge, estimated time of arrival and all other necessary information. The Contractor should also provide the Client with an advance Notice of Shipment for outstanding balances of consignments.

One (1) set of negotiable documents shall be submitted by the Contractor to the Client at least one week before the arrival of the supplies at the port of entry and, if not received, the Contractor will be responsible for any consequent expenses. All documents should be marked "ON ARRIVAL NOTIFY **NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION, 78 MARCUS GARVEY DRIVE, KINGSTON 13, JAMAICA, TELEPHONE (876) 923-6920, (Extn. 3007), FAX (876) 923-9593**".

Negotiable documents shall include an original bill of lading or air waybill showing the declared value for carriage, Contractor's original signed invoice, original signed Caricom Invoice and detailed packing list(s). The Contractor's invoice should bear the Client's purchase order number, and indicate separately for each item: description, quantity, CIF price, total CIF amount and expiry date. The invoice shall show separately the cost of freight and insurance.

The negotiable documents above shall be accompanied by a Certificate of Insurance providing adequate cover for supplies of the kind agreed under this Contract and naming the Client as the beneficiary. The marine/air insurance shall be in an amount equal to 110% of the CIF value of the supplies from "warehouse to warehouse" on "All Risks" basis including War Risks and Strike clauses. Insurance coverage must be effective up to sixty (60) days following unloading at the port of destination.

The Contractor shall also supply a Certificate of Analysis in triplicate stating that the supplies meet the standards stipulated under these Conditions.

For supplies of domestic origin the Contractor shall submit an original and a copy of the Delivery Note and Contractor's invoice(s). The invoice should bear the Client's purchase order number and indicate for each item: description, quantity, unit price, total value, and expiry date. The Contractor shall also supply a Certificate of Analysis in triplicate as described in paragraph above.

Testing

The Client may at any time during the eighteen (18) month period following delivery submit to an independent analyst for evaluation any or all of the supplies and if any or all of such supplies are found to be deficient due to no fault or negligence of the Client, the Client shall immediately send the certificate of findings to the Contractor.

The Contractor unless he can successfully refute the findings of the independent analyst, is then liable to replace at its own expense, within 30 days, the entire quantity of supplies delivered in that batch to which the deficient items belong with fresh supplies satisfying the standards set out in paragraph 3.1.

The Contractor shall not be exempted from the liability stated above on the ground that the date of expiration of this Contract preceded the date of receipt of the certificate of finding.

Inferior Products

The Client reserves the right to return to the Contractor all supplies that do not meet the required quality as stipulated in the Schedule of Requirements or in the Contractor's tender provided such standard was found acceptable to the Client. The expense of returning such supplies shall be borne by the Contractor and the supplies shall be replaced by the Contractor at no additional expense to the Client.

- 5.1 The contract price is _____.
- 5.2 The currency of payment to the Contractor is United States Dollars.
- 5.4 Payment for deliveries of imported supplies shall be made by the Client in US\$ currency by Sight Draft, Letter of Credit or Open Account in favour of the Contractor to any bank which he nominates on the Payment Form provided in the Tender Documents.

All necessary documents shall be airmailed or dispatched by courier to the Client or Bank(s) where applicable, in advance of arrival of the vessel transporting the supplies.

Payment for Supplies of domestic origin shall be made by the Client in United States Dollar (US\$) currency within 30 days or longer as agreed with the Contractor, of the Client's receipt of the supplies in satisfactory condition and documents as specified under these Conditions and/or any other documents as may otherwise be required by the Client.

- 5.7 An unexcused delay by the Contractor in the performance of its delivery obligations shall render the Contractor liable to imposition of liquidated damages and/or termination of the Contract for default. Any cost in excess of the contract price and charges incidental to such purchases shall be recoverable from the Contractor.

If at any time during performance of the Contract, the Contractor should encounter conditions impeding timely delivery of the supplies, the Contractor shall promptly notify the Client in writing of the fact of the delay, its likely duration and its cause(s).

The delivery and acceptance of any supplies after the delivery time agreed by the parties shall not be deemed a waiver of the right of the Client either to terminate this Contract or to require the delivery of any further supplies in accordance with this Contract.

- 5.8 A sum equivalent to 0.5% per week of the delivered price of the delayed supplies for each week of delay until actual delivery of performance, up to a maximum deduction of 10% of the delayed supplies' Contract Price. Once the maximum is reached, the Client may consider termination of the Contract.
- 7.2 Disputes shall be settled by arbitration in accordance with the following provisions:

1. Selection of Arbitrators

Each dispute submitted by a Party to arbitration shall be heard by a sole arbitrator or an arbitration panel composed of three arbitrators, in accordance with the following provisions:

- (a) Where the Parties agree that the dispute concerns a technical matter, they may agree to within fourteen (14) days appoint a sole arbitrator for the matter in dispute.
- (b) Where the Parties do not agree that the dispute concerns a technical matter, the Client and the Contractor shall each appoint one arbitrator, and these two arbitrators shall jointly appoint a third arbitrator, who shall chair the arbitration panel. If the arbitrator within twenty (20) days after the latter of the two arbitrators named by the Parties has not been appointed, the third arbitrator shall, at the request of either Party, be appointed by the Chairman of the National Contracts Commission.
- (c) If, in a dispute subject to Clause SC 7.2 1 (b), one Party fails to appoint its arbitrator within fourteen (14) days after the other Party has appointed its arbitrator, the Party which has named an arbitrator may apply to the Chairman of the National Contracts Commission to appoint a sole arbitrator for the matter in dispute, and the arbitrator appointed pursuant to such application shall be the sole arbitrator for that dispute.

2. **Rules of Procedure**

Except as stated herein, arbitration proceedings shall be conducted in accordance with the rules or procedure for arbitration, pursuant to the Laws of Jamaica as in force on the date of this Contract.

3. **Substitute Arbitrators**

If for any reason an arbitrator is unable to perform his function, a substitute shall be appointed in the same manner as the original arbitrator.

4. **Miscellaneous**

In any arbitration proceeding hereunder:

- (a) proceedings shall, unless otherwise agreed by the Parties, be held in Jamaica;
- (b) the English language shall be the official language for all purposes; and
- (c) the decision of the sole arbitrator or of a majority of the arbitrators (or of the third arbitrator if there is no such majority) shall be final and binding and shall be enforceable in any court of competent jurisdiction, and the Parties hereby waive any objections to or claims of immunity in respect of such enforcement.

TENDER FORM

..... 2011/2013

**TO: The Chief Executive Officer
 National Health Fund Pharmaceutical Division
 78 Marcus Garvey Drive
 Kingston 13
 Jamaica, West Indies**

Gentlemen:

Having examined the Tender Documents, the receipt of which is hereby duly acknowledged

I/WE
(Full Name of Tenderer)

of
(Full address of Tenderer)

.....

hereby offer to supply and deliver supplies in conformity with the said Tender Documents for the total bid price of: and in accordance with the unit prices inserted on the attached Schedule of Requirements. I/We am/are not interested in supplying or delivering those items for which I/we have not submitted any information.

I/We agree that on receipt of your Notice of Acceptance, I/we will be deemed to be your contractor/s in accordance with the terms set out in this Tender Form and the annexed Instructions to Tenderers, Schedule of Requirements, Conditions of Contract, the Notice of Acceptance and any purchase orders you may make under this agreement.

I/We agree that I/we will give my/our personal attention to the faithful performance of the Contract and that I/we will not assign, transfer, convey, sublet or otherwise dispose of this Contract or my/our rights, title or interest in or to the same or any part thereof without your previous written consent.

I/We agree to furnish any testimonials of evidence of my/our financial ability, prior experience, ability to perform the contract, however and whenever you request these.

I/We agree to abide by this tender for a period of not less that 180 days from the deadline for the submission of tenders under paragraph 7 of the Instructions to Tenderers and it shall remain binding upon me/us and may be accepted at any time before the expiration of that period.

I/We understand that you are not bound to accept the lowest or any tender you may receive.

.....
Signature of Tenderers

.....
(in the capacity of)

PAYMENT FORM

PLEASE INDICATE PAYMENT TERMS BY TICKING THE APPROPRIATE CHOICE

NAME AND ADDRESS OF SUPPLIER

.....

.....

TELEPHONE Nos.

TELEFAX Nos.

E-MAIL ADDRESS

OPEN ACCOUNT Payment by Wire Transfer or Cheque Upon Presentation of Shipping Documents

_____ - 30 days

_____ - 60 days

_____ - 90 days

_____ - 120 days

_____ - 180 days

_____ - 240 days

SIGHT DRAFT

_____ - 30 days

_____ - 60 days

_____ - 90 days

_____ - 120 days

NAME AND ADDRESS OF BANKERS

.....

ACCOUNT NUMBER

(Mandatory for Wire Transfer)

ADDENDUM

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013

PLEASE NOTE THAT THE FULL DESCRIPTION OF ITEM DR0179 STARTS ON PAGE 10 AND CONTINUES OVERLEAF ON PAGE 11.

PLEASE NOTE THAT THE FULL DESCRIPTION OF ITEM DR0379 STARTS ON PAGE 21 AND CONTINUES OVERLEAF ON PAGE 22.

PLEASE NOTE THAT THE FULL DESCRIPTION OF ITEM DR0491 STARTS ON PAGE 27 AND CONTINUES OVERLEAF ON PAGE 28.

BIDDERS ARE REMINDED TO INPUT, ON TENDER FORM, THE GRAND TOTAL OF ALL BIDS SUBMITTED.

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0001	ACARBOSE	100 MG	TABLET	90'S	13,500 **					
DR0002	ACARBOSE	50 MG	TABLET	84'S	16,200 **					
DR0003	ACETAZOLAMIDE*	250 MG	TABLET	500'S	2,250					
DR0004	ACETIC ACID GLACIAL		BULK	2 L	750					
DR0005	ACETYLCYSTEINE*	200 MG/ML	INJECTION	10 ML	1,050					
DR0006	ACETYLSALICYLIC ACID*	325 MG	TABLET	1000'S	450					
DR0007	ACETYLSALICYLIC ACID*	81MG	TABLET	120'S	150,000					
DR0008	ACID CONCENTRATE FOR BICARBONATE DIALYSIS (OFD 2251-3B) (2. 0 K, 2.5 CA)		BULK	16.5 GAL	2,430					
DR0009	ACID CONCENTRATE FOR BICARBONATE DIALYSIS (OFD 2301-3B) (2. 0 K, 3.0CA)		BULK	16.5 GAL	1,297					
DR0010	ACTINOMYCIN D*	500 MG/VIAL	INJECTION	VIAL	980					
DR0011	ACYCLOVIR	800 MG	TABLET	100'S	3,000					
DR0012	ACYCLOVIR (EYE)	3%	OINTMENT	5 G	750					
DR0013	ACYCLOVIR SODIUM	250 MG	INJECTION	VIAL	4,500					
DR0014	ACYCLOVIR*	400 MG	TABLET	100'S	5,200					
DR0015	ACYCLOVIR*	200MG/5ML	SUSPENSION	125 ML	900					
DR0016	ACYCLOVIR*	200 MG	TABLET	100 'S	4,200					
DR0017	ADENOSINE*	6MG/2ML	INJECTION	2 ML	1,275					
DR0018	ADRENALINE*	0.1%	INJECTION	2 ML	54,000					
DR0019	ALBENDAZOLE	400 MG	TABLET	EACH	27,000 **					
DR0020	ALBENDAZOLE	200 MG/5ML	SUSPENSION	10 ML	45,000 **					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0021	ALBUMIN (HUMAN SERUM) (SALT POOR) WITH ADMINISTRATION SET*	25%	INJECTION	50 ML	4,650					
DR0022	ALCOHOL	70%	BULK	3.78 L	22,500 **					
DR0023	ALCURONIUM CHLORIDE*	5 MG/ML	INJECTION	2 ML	30,500					
DR0024	ALLOPURINOL*	100 MG	TABLET	100'S	6,600					
DR0025	ALLOPURINOL*	300 MG	TABLET	100'S	1,500					
DR0026	ALPRAZOLAM	0.25MG	TABLET	100'S	1,800					
DR0027	ALPRAZOLAM	0.5 MG	TABLET	100'S	900					
DR0028	ALPRAZOLAM	1 MG	TABLET	100'S	450					
DR0029	ALUMINIUM HYDROXIDE) MAGNESIUM HYDROXIDE) STRENGTH IS PER 5ML	250MG) 500MG)	SUSPENSION	350 ML	18,500 **					
DR0030	ALUMINIUM HYDROXIDE) MAGNESIUM HYDROXIDE)	270 MG) 75 MG)	TABLET	500'S	8,800 **					
DR0031	AMANTADINE HYDROCHLORIDE	100 MG	CAPSULE	56'S	300					
DR0032	AMANTADINE HYDROCHLORIDE	50 MG/5 ML	SYRUP	150 ML	450					
DR0033	AMETHOCAINE SULPHATE (EYE)*	0.5%	DROPS	0.5 ML	1,500					
DR0034	AMIKACIN SULPHATE PEADIATRIC*	50MG/ML	INJECTION	2 ML	1,800					
DR0035	AMIKACIN SULPHATE*	500 MG	INJECTION	VIAL	12,000					
DR0036	AMINO-ACIDS WITH NITROGEN (EQUIV. TO VAMIN N)*		INJECTION	500 ML	285					
DR0037	AMINO-ACIDS) GLUCOSE 10%) (EQUIV. TO AMINOSOL) *		INJECTION	500 ML	4,050					
DR0038	AMINOCAPROIC ACID*	400 MG/ML	INJECTION	VIAL	225					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0039	AMINOCAPROIC ACID*	300 MG/5 ML	SYRUP	480 ML	150					
DR0040	AMINOPHYLLINE (I.V.)*	0.25 G/10ML	INJECTION	10 ML	26,800 **					
DR0041	AMIODARONE*	50 MG/ML	INJECTION	3 ML	1,800					
DR0042	AMIODARONE*	200 MG	TABLET	28'S	168					
DR0043	AMITRIPTYLINE HYDROCHLORIDE*	25 MG	TABLET	1000'S	4,500					
DR0044	AMLODIPINE	5 MG	TABLET	100'S	18,000					
DR0045	AMLODIPINE	10 MG	TABLET	100'S	30,000					
DR0046	AMMONIUM CHLORIDE		POWDER	500 G	189					
DR0047	AMOXYCILLIN) CLAVULANIC ACID)	250 MG 62.5 MG	SUSPENSION	100 ML	9,000					
DR0048	AMOXYCILLIN)* CLAVULANIC ACID)	1 G) 200 MG)	INJECTION	VIAL	270,000 **					
DR0049	AMOXYCILLIN)* CLAVULANIC ACID)	500 MG) 100 MG)	INJECTION	VIAL	216,000 **					
DR0050	AMOXYCILLIN)* CLAVULANIC ACID)	400MG) 57MG)	SUSPENSION	70 ML	105,000					
DR0051	AMOXYCILLIN)* CLAVULANIC ACID)	500 MG) 125 MG)	TABLET	14'S	97,500					
DR0052	AMOXYCILLIN)* CLAVULANIC ACID)	875 MG) 125 MG)	TABLET	14'S	105,000					
DR0053	AMOXYCILLIN)* CLAVULANIC ACID)	200MG) 28MG)	SUSPENSION	70 ML	86,500					
DR0054	AMOXYCILLIN*	250 MG	CAPSULE	1000'S	6,450					
DR0055	AMOXYCILLIN*	500 MG	CAPSULE	1000'S	2,550					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0056	AMOXYCILLIN*	250 MG	INJECTION	VIAL	127,500					
DR0057	AMOXYCILLIN*	500 MG	INJECTION	VIAL	120,000					
DR0058	AMOXYCILLIN*	125 MG/5ML	SUSPENSION	100 ML	108,000					
DR0059	AMOXYCILLIN*	250MG/5ML	SUSPENSION	100 ML	60,000					
DR0060	AMPHOTERICIN B (I.V.)*	50 MG	INJECTION	10 ML	750					
DR0061	ANASTROZOLE	1 MG	TABLET	28'S	5,400					
DR0062	ANTI-D IMMUNOGLOBULIN (EQUIVALENT TO RHOGAM)	300 MCG	INJECTION	VIAL	3,510 **					
DR0063	ARACHIS		OIL	2 L	108					
DR0064	ATENOLOL*	50 MG	TABLET	28'S	68,500					
DR0065	ATENOLOL*	100 MG	TABLET	28'S	95,000					
DR0066	ATORVASTATIN	10 MG	TABLET	20'S	14,000					
DR0067	ATORVASTATIN	20 MG	TABLET	20'S	16,500					
DR0068	ATORVASTATIN	40 MG	TABLET	20'S	1,650					
DR0069	ATROPINE SULPHATE		POWDER	25 G	90					
DR0070	ATROPINE SULPHATE (EYE)*	1%	DROPS	10 ML	2,700					
DR0071	ATROPINE SULPHATE*	0.6 MG/ML	INJECTION	1 ML	78,000					
DR0072	AURALGAN EAR		DROPS	10 ML	2,700					
DR0073	AZATHIOPRINE*	50 MG	TABLET	100'S	1,650					
DR0074	AZITHROMYCIN	200 MG/5 ML	SUSPENSION	15 ML	3,750					
DR0075	AZITHROMYCIN	500 MG	TABLET	3'S	10,800					
DR0076	AZITHROMYCIN	250 MG	TABLET	4'S	4,500					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0077	BACITRACIN ZINC)* NEOMYCIN SULPHATE) TYROTHRICIN)	500 IU) 3 MG) 2 MG)	OINTMENT	15 G	6,600					
DR0078	BACLOFEN	10 MG	TABLET	84'S	300					
DR0079	BARIUM SULPHATE FOR SUSPENSION (EQUIV TO EZ-PAQUE)		POWDER	25 LB	405					
DR0080	BARIUM SULPHATE FOR SUSPENSION (EQUIV TO EZ-HD)		POWDER	25 LB	351					
DR0081	BECLOMETHASONE	50 MCG	NASAL SPRAY	200 DOSES	450					
DR0082	BECLOMETHASONE INHALER*	50 MCG/DOSE	INHALER	200 DOSES	163,500 **					
DR0083	BECLOMETHASONE INHALER*	250 MCG/DOSE	INHALER	200 DOSES	1,500					
DR0084	BENDROFLUAZIDE) RESERPINE)	5 MG) 0.15 MG)	TABLET	250'S	12,000					
DR0085	BENDROFLUAZIDE*	5 MG	TABLET	2000'S	1,125					
DR0086	BENDROFLUAZIDE*	2.5 MG	TABLET	1000'S	1,950					
DR0087	BENZATHINE PENICILLIN*	2.4 MEGA UNIT	INJECTION	VIAL	54,000					
DR0088	BENZOIC ACID		POWDER	500 G	81					
DR0089	BENZOIN COMPOUND		TINCTURE	500 ML	540					
DR0090	BENZOYL PEROXIDE	5%	GEL	30 G	1,800					
DR0091	BENZOYL PEROXIDE	10%	GEL	30 G	1,800					
DR0092	BENZTROPINE MESYLATE*	1 MG/ML	INJECTION	2 ML	21,600					
DR0093	BENZTROPINE MESYLATE*	2 MG	TABLET	1000'S	9,000					
DR0094	BENZYL BENZOATE (EMULSION)*	25%	BULK	2 LITRE	562					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0095	BENZYL PENICILLIN*	1 MEGAUNIT	INJECTION	VIAL	75,000					
DR0096	BERACTANT	25 MG/ML	SOLUTION	8 ML	540					
DR0097	BETAMETHASONE SCALP APPLICATION*	1%	SOLUTION	50 ML	1,050					
DR0098	BETAMETHASONE SODIUM PHOSPHATE)* NEOMYCIN) (EYE/EAR/NOSE)	0.1%) 0.5%)	DROPS	5 ML	13,500 **					
DR0099	BETAMETHASONE SODIUM PHOSPHATE* (EYE/EAR/NOSE)	0.1%	DROPS	5 ML	18,900					
DR0100	BETAMETHASONE SODIUM PHOSPHATE*	4 MG/ML	INJECTION	1 ML	270					
DR0101	BETAMETHASONE VALERATE*	0.1%	CREAM	15 G	16,200					
DR0102	BETAMETHASONE VALERATE*	0.1%	OINTMENT	15 G	9,450					
DR0103	BETAXOLOL	0.25%	DROPS	10 ML	7,020					
DR0104	BISACODYL	5 MG	TABLET	1000'S	810					
DR0105	BISACODYL	5 MG	SUPPOSITORY	100'S	90					
DR0106	BISACODYL	10 MG	SUPPOSITORY	100'S	90					
DR0107	BISMUTH SUBSALICYLATE	262 MG/5ML	SUSPENSION	250 ML	225					
DR0108	BISOPROLOL	5 MG	TABLET	28'S	135					
DR0109	BISOPROLOL	10 MG	TABLET	28'S	75					
DR0110	BLEOMYCIN SULPHATE	15 MG	INJECTION	VIAL	1,200					
DR0111	BORTEZOMIB	3.5 MG	INJECTION	VIAL	270					
DR0112	BROMHEXINE CHLORIDE	8 MG/5 ML	ELIXIR	100 ML	16,500					
DR0113	BUDESONIDE RESPIRATOR	500 MCG/ ML	SOLUTION	20 X 2 ML	1,350					
DR0114	BUDESONIDE RESPIRATOR	250 MCG/ML	SOLUTION	20 X 2 ML	3,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0115	BUDESONIDE) FORMOTEROL)	160 MCG) 4.5 MCG)	TURBUHALER	60 DOSES	2,430					
DR0116	BUDESONIDE) FORMOTEROL)	80 MCG) 4.5 MCG)	TURBUHALER	60 DOSES	3,000					
DR0117	BUDESONIDE) FORMOTEROL)	320 MCG) 9.0 MCG)	TURBUHALER	60 DOSES	2,160					
DR0118	BUPIVACAINE HYDROCHLORIDE) GLUCOSE) (HEAVY)*	0.5%) 80MG/ML)	INJECTION	4 ML	8,000					
DR0119	BUPIVACAINE HYDROCHLORIDE* (WITHOUT PRESERVATIVE)	0.5%	INJECTION	10 ML	12,000					
DR0120	BUPIVACAINE HYDROCHLORIDE* (WITHOUT PERSERVATIVE)	0.25%	INJECTION	10 ML	16,250					
DR0121	BUSULPHAN	2 MG	TABLET	100'S	108					
DR0122	CALAMINE		POWDER	1 KG	135					
DR0123	CALCIPOTRIOL	50 MCG/ G	OINTMENT	120 G	300					
DR0124	CALCITRIOL	0.25 MCG	CAPSULE	100'S	2,700					
DR0125	CALCITRIOL	2 MCG/ML	INJECTION	1 ML	540					
DR0126	CALCIUM ACETATE*	1G	TABLET	180'S	600					
DR0127	CALCIUM CHLORIDE*	10%	INJECTION	10 ML	5,400					
DR0128	CALCIUM DISODIUM EDETATE	200 MG/ML	INJECTION	5 ML	324					
DR0129	CALCIUM FOLINATE (FOLINIC ACID)*	50 MG	INJECTION	VIAL	12,000 **					
DR0130	CALCIUM FOLINATE (FOLINIC ACID)*	15 MG	CAPSULE	30'S	225					
DR0131	CALCIUM FOLINATE (FOLINIC ACID)*	300 MG	INJECTION	VIAL	2,160					
DR0132	CALCIUM GLUCONATE	650 MG	TABLET	1000'S	225					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0133	CALCIUM GLUCONATE*	10%	INJECTION	10 ML	27,000					
DR0134	CANASOL EYE	0.1%	DROPS	5 ML	2,250					
DR0135	CAPTOPRIL*	12.5 MG	TABLET	100'S	2,250					
DR0136	CAPTOPRIL*	25 MG	TABLET	100'S	13,500					
DR0137	CAPTOPRIL*	50 MG	TABLET	100'S	13,500					
DR0138	CARBAMAZEPINE (CONTROLLED RELEASE)*	200 MG	TABLET	50'S	10,500 **					
DR0139	CARBAMAZEPINE (CONTROLLED RELEASE)*	400 MG	TABLET	30'S	4,500					
DR0140	CARBAMAZEPINE*	100 MG	TABLET	84'S	27,000					
DR0141	CARBAMAZEPINE*	200 MG	TABLET	500'S	10,800					
DR0142	CARBAMAZEPINE*	100MG/5ML	SYRUP	100 ML	5,000					
DR0143	CARBIMAZOLE*	5 MG	TABLET	100'S	20,250					
DR0144	CARBOPLATIN*	50 MG	INJECTION	5 ML	1,620					
DR0145	CARBOPLATIN*	450 MG	INJECTION	45 ML	2,700					
DR0146	CARVEDILOL	6.25 MG	TABLET	28'S	10,500					
DR0147	CARVEDILOL	12.5 MG	TABLET	28'S	6,000					
DR0148	CARVEDILOL	25 MG	TABLET	28'S	6,000					
DR0149	CASTOR		OIL	500 ML	165					
DR0150	CEFOTAXIME (I.M/I.V)	1G	INJECTION	VIAL	5,400 **					
DR0151	CEFOTAXIME (I.V/I.M)	500 MG	INJECTION	VIAL	5,400					
DR0152	CEFTAZIDIME (I.M./I.V.)	1 G	INJECTION	VIAL	66,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0153	CEFTAZIDIME (I.M./I.V.)	0.5 G	INJECTION	VIAL	42,000					
DR0154	CEFTRIAZONE (I.M./I.V.)*	250 MG/VIAL	INJECTION	2 ML	67,500					
DR0155	CEFTRIAZONE (I.M./I.V.)*	1 G	INJECTION	10 ML	360,000 **					
DR0156	CEFUROXIME AXETIL	250 MG	TABLET	50'S	3,000					
DR0157	CEFUROXIME AXETIL	125 MG/5 ML	SUSPENSION	100 ML	18,000					
DR0158	CEFUROXIME AXETIL	500 MG	TABLET	50'S	7,500					
DR0159	CEFUROXIME AXETIL	250 MG/5 ML	SUSPENSION	100 ML	6,000					
DR0160	CEFUROXIME SODIUM*	750 MG	INJECTION	VIAL	7,500					
DR0161	CEFUROXIME SODIUM*	1.5 G	INJECTION	VIAL	13,500					
DR0162	CETRIMIDE	0.5%	CREAM	15 G	1,500					
DR0163	CETRIMIDE*	1%	SOLUTION	120 ML	2,700					
DR0164	CHARCOAL (ACTIVATED)		POWDER	500 G	162					
DR0165	CHARCOAL (ACTIVATED)	260 MG	CAPSULE	100'S	450					
DR0166	CHARCOAL ACTIVATED SILVER (EQUIV TO IMPREGNATED GAUZE)*		DRESSING	6.5 CM X 9.5 CM	2,700					
DR0167	CHLORAL HYDRATE*	4%	SOLUTION	100 ML	60					
DR0168	CHLORAMBUCIL*	2 MG	TABLET	25'S	225					
DR0169	CHLORAMPHENICOL	250 MG	CAPSULE	1000'S	324					
DR0170	CHLORAMPHENICOL (EAR)*	0.5%	DROPS	15 ML	10,500					
DR0171	CHLORAMPHENICOL (EYE)*	0.5%	DROPS	10 ML	13,500					
DR0172	CHLORAMPHENICOL (EYE)*	1%	OINTMENT	4 G	945					
DR0173	CHLORAMPHENICOL I.M./I.V.	1 G	INJECTION	VIAL	3,750					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0174	CHLORAMPHENICOL PALMITATE	125 MG/5ML	SUSPENSION	120 ML	810					
DR0175	CHLORAMPHENICOL) * DEXAMETHASONE) (EYE)	0.5%) 0.1%)	DROPS	10 ML	1,800					
DR0176	CHLORHEXIDINE (OBSTETRIC)	1%	CREAM	250 ML	1,200					
DR0177	CHLORHEXIDINE GLUCONATE (EQ. TO HIBISCRUB)	4%	BULK	5 LITRE	1,080					
DR0178	CHLORHEXIDINE GLUCONATE (EQ. TO HIBITANE CONC)	5%	SOLUTION	5 L	300					
DR0179	CHLORHEXIDINE GLUCONATE) CETRIMIDE) (CONCENTRATE)	1.5%) 1.5%)	BULK	5 L	1,620					
DR0180	CHLORHEXIDINE MOUTH WASH	0.2%	SOLUTION	150 ML	900					
DR0181	CHLORINATED LIME		POWDER	2.5 KG	105					
DR0182	CHLOROCRESOL		POWDER	100 G	120					
DR0183	CHLOROQUINE PHOSPHATE	250 MG	TABLET	100'S	600					
DR0184	CHLORPHENIRAMINE MALEATE*	2 MG/5ML	SYRUP	150 ML	33,000 **					
DR0185	CHLORPHENIRAMINE MALEATE*	4 MG	TABLET	1000'S	1,500					
DR0186	CHLORPHENIRAMINE MALEATE*	10 MG	INJECTION	2 ML	60,000 **					
DR0187	CHLORPROMAZINE HYDROCHLORIDE*	25 MG/ML	INJECTION	2 ML	75,000					
DR0188	CHLORPROMAZINE HYDROCHLORIDE*	50 MG	TABLET	1000'S	1,050					
DR0189	CHLORPROMAZINE HYDROCHLORIDE*	100 MG	TABLET	1000'S	3,240					
DR0190	CHLORPROMAZINE HYDROCHLORIDE*	25 MG/5ML	SYRUP	100 ML	450					
DR0191	CHLORPROMAZINE HYDROCHLORIDE*	25 MG	TABLET	1000'S	1,800					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0192	CHOLESTYRAMINE CHLORIDE		POWDER	378 G	112					
DR0193	CICLOPIROXOLAMINE	1%	SOLUTION	3.5 ML	330					
DR0194	CINNARIZINE	75 MG	TABLET	84'S	675					
DR0195	CIPROFLOXACIN HYDROCORTISONE (EAR)	0.3%	DROPS	10 ML	900					
DR0196	CIPROFLOXACIN	2 MG/ML	INJECTION	50 ML	1,800					
DR0197	CIPROFLOXACIN (EYE)	0.3%	DROPS	5 ML	2,100					
DR0198	CIPROFLOXACIN (EYE)	0.3%	OINTMENT	3.5 G	1,350					
DR0199	CIPROFLOXACIN HYDROCHLORIDE	250 MG	TABLET	20'S	27,000					
DR0200	CIPROFLOXACIN HYDROCHLORIDE	500 MG	TABLET	20'S	40,500					
DR0201	CIPROFLOXACIN HYDROCHLORIDE	2 MG/ML	INJECTION	50 ML	1,800					
DR0202	CISATRACURIUM BESYLATE*	10 MG/5 ML	INJECTION	5 ML	60,000					
DR0203	CISPLATIN*	50 MG	INJECTION	VIAL	3,000					
DR0204	CLARITHROMYCIN	500 MG	TABLET	14'S	1,500					
DR0205	CLARITHROMYCIN	250 MG	TABLET	14'S	2,250					
DR0206	CLEMASTINE FUMARATE	1 MG	TABLET	60'S	300					
DR0207	CLINDAMYCIN	150 MG	CAPSULE	100'S	4,500 **					
DR0208	CLINDAMYCIN	300 MG	CAPSULE	100'S	2,250					
DR0209	CLINDAMYCIN	150 MG/ML	INJECTION	2 ML	102,000 **					
DR0210	CLINDAMYCIN	75 MG/5ML	SUSPENSION	100 ML	900					
DR0211	CLINDAMYCIN	1%	SOLUTION	60 ML	1,800					
DR0212	CLINDAMYCIN	1%	GEL	30 G	2,400					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0213	CLOBETASOL PROPIONATE (SKIN)*	0.05%	CREAM	25 G	5,400					
DR0214	CLOBETASOL PROPIONATE (SKIN)*	0.05%	OINTMENT	25 G	2,700					
DR0215	CLOFAZIMINE*	100 MG	CAPSULE	100'S	225					
DR0216	CLOMIPHENE CITRATE	50 MG	TABLET	10'S	450					
DR0217	CLONAZEPAM*	0.5 MG	TABLET	100'S	112					
DR0218	CLONAZEPAM*	1 MG/ML	INJECTION	1 ML	45					
DR0219	CLONAZEPAM*	2 MG	TABLET	100'S	60					
DR0220	CLOPIDOGREL	75 MG	TABLET	30'S	27,000					
DR0221	CLOTRIMAZOLE (TOPICAL)	1%	SOLUTION	20 ML	900					
DR0222	CLOTRIMAZOLE MOUTH PAINT*	1%	SOLUTION	20 ML	975					
DR0223	CLOTRIMAZOLE*	1%	CREAM	20 G	81,000					
DR0224	CLOTRIMAZOLE*	100 MG	PESSARIES	6'S	94,500					
DR0225	CLOXACILLIN *	500 MG	INJECTION	VIAL	8,100					
DR0226	CLOXACILLIN*	500 MG	CAPSULE	100'S	6,000 **					
DR0227	CLOXACILLIN*	250 MG	CAPSULE	1000'S	3,000 **					
DR0228	CLOXACILLIN*	250 MG	INJECTION	VIAL	9,000					
DR0229	CLOXACILLIN*	125 MG/5ML	SYRUP	100 ML	27,000					
DR0230	CLOZAPINE	25 MG	TABLET	100'S	150					
DR0231	CLOZAPINE	100 MG	TABLET	50'S	135					
DR0232	COAL TAR		SOLUTION	500 ML	162					
DR0233	COCAINE HYDROCHLORIDE		POWDER	25 G	12					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0234	CODEINE PHOSPHATE		POWDER	25 G	90					
DR0235	CODEINE PHOSPHATE	30 MG	TABLET	20'S	300					
DR0236	COLAGENASE		GEL	30 G	150					
DR0237	CORTICOSPORIN (EAR)		DROPS	10 ML	270					
DR0238	CORTISONE ACETATE	25 MG	TABLET	56'S	300					
DR0239	CYCLOPENTOLATE (EYE)	1%	DROPS	10 ML	225					
DR0240	CYCLOPHOSPHAMIDE*	500 MG	INJECTION	VIAL	3,600					
DR0241	CYCLOPHOSPHAMIDE*	1 G	INJECTION	VIAL	4,500					
DR0242	CYCLOPHOSPHAMIDE*	50 MG	TABLET	50'S	540					
DR0243	CYCLOPHOSPHAMIDE*	200 MG	INJECTION	VIAL	2,250					
DR0244	CYCLOSPORIN	25 MG	CAPSULE	30'S	225					
DR0245	CYCLOSPORIN	100 MG/ML	ORAL SOLUTION	50 ML	112					
DR0246	CYPROTERONE ACETATE	50 MG	TABLET	50'S	2,160					
DR0247	CYPROTERONE ACETATE	100 MG	TABLET	30'S	5,400					
DR0248	CYTOSINE ARABINOSIDE*	100 MG/VIAL	INJECTION	VIAL	2,100					
DR0249	CYTOSINE ARABINOSIDE*	500 MG/VIAL	INJECTION	VIAL	2,100					
DR0250	DACARBAZINE	100 MG/VIAL	INJECTION	10 ML	1,350					
DR0251	DACARBAZINE	200 MG/VIAL	INJECTION	20 ML	2,250					
DR0252	DALTEPARIN SODIUM	2,500 U/ML	INJECTION	0.2 ML	5,000					
DR0253	DALTEPARIN SODIUM	5,000 U/ML	INJECTION	0.2 ML	2,500					
DR0254	DANTROLENE	25 MG	INJECTION	VIAL	60					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0255	DAPSONE*	100 MG	TABLET	28'S	1,275					
DR0256	DAUNORUBICIN HYDROCHLORIDE	20 MG	INJECTION	VIAL	5,400					
DR0257	DESFERRIOXAMINE MESYLATE*	500 MG	INJECTION	VIAL	150					
DR0258	DESMOPRESSIN INTRANASAL	100MCG/ML	SPRAY	2.5 ML	675					
DR0259	DEXAMETHASONE	0.5 MG	TABLET	100'S	600					
DR0260	DEXAMETHASONE	2 MG	TABLET	500'S	330					
DR0261	DEXAMETHASONE (EYE)	0.1%	DROPS	5 ML	450					
DR0262	DEXAMETHASONE SODIUM PHOSPHATE*	4 MG/ML	INJECTION	2 ML	140,000 **					
DR0263	DEXAMETHASONE*	5 MG	TABLET	500'S	1,620					
DR0264	DEXTROSE	20%	INJECTION	500 ML	4,500					
DR0265	DEXTROSE 10% IN WATER (I.V.)*		INFUSION	500 ML	49,500 **					
DR0266	DEXTROSE 5% IN 0.2 % NORMAL SALINE (I.V.)*		INFUSION	500 ML	108,000					
DR0267	DEXTROSE 5% IN 0.45% NORMAL SALINE (I.V.)*		INFUSION	500 ML	135,000					
DR0268	DEXTROSE 5% IN NORMAL SALINE (I.V.)*		INFUSION	500 ML	150,000					
DR0269	DEXTROSE 5% IN WATER (I.V.)*		INFUSION	500 ML	270,000 **					
DR0270	DEXTROSE*	50%	INJECTION	50 ML	70,000					
DR0271	DIAZEPAM*	5 MG/ML	INJECTION	2 ML	67,500					
DR0272	DIAZEPAM*	2 MG	TABLET	1000'S	150					
DR0273	DIAZEPAM*	5 MG	TABLET	1000'S	750					
DR0274	DIAZEPAM*	10 MG	SUPPOSITORY	6'S	1,650					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0275	DICLOFENAC SODIUM S.R.*	75 MG	TABLET	100'S	26,000					
DR0276	DICLOFENAC POTASSIUM*	1.50%	DROPS	15 ML	8,800					
DR0277	DICLOFENAC POTASSIUM*	9MG/5ML	SUSPENSION	120 ML	75,000					
DR0278	DICLOFENAC POTASSIUM*	12.5 MG	SUPPOSITORY	10'S	300					
DR0279	DICLOFENAC POTASSIUM*	50 MG	TABLET	50'S	20,000					
DR0280	DICLOFENAC SODIUM S.R.*	100 MG	TABLET	100'S	4,050					
DR0281	DICLOFENAC SODIUM*	50 MG	TABLET	500'S	16,500					
DR0282	DICLOFENAC SODIUM*	75 MG	INJECTION	3 ML	490,000 **					
DR0283	DICLOFENAC SODIUM*	1%	GEL	30 G	58,000					
DR0284	DICLOFENAC SODIUM*	25 MG	TABLET	100'S	9,000					
DR0285	DIFLUCORTOLONE VALERATE) ISCOCONAZOLE NITRATE) NEOMYCIN SULPHATE)	5 MG) 10 MG) 5 MG)	CREAM	15 G	8,550					
DR0286	DIGOXIN*	0.25 MG/ML	INJECTION	3 ML	4,000					
DR0287	DIGOXIN*	0.05 MG/ML	ELIXIR	60 ML	2,700					
DR0288	DIGOXIN*	0.25 MG	TABLET	500'S	2,250					
DR0289	DIGOXIN*	0.125 MG	TABLET	500'S	1,950					
DR0290	DILTIAZEM	60 MG	TABLET	100'S	675					
DR0291	DIMENHYDRINATE	15 MG/5ML	ELIXIR	150 ML	900					
DR0292	DIMENHYDRINATE*	50 MG/ML	INJECTION	5 ML	98,000 **					
DR0293	DIMENHYDRINATE*	50 MG	TABLET	1000'S	720					
DR0294	DIMENHYDRINATE*	50 MG	SUPPOSITORY	10'S	120					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0295	DIMERCAPROL*	50MG/ML	INJECTION	2 ML	270					
DR0296	DIOSMIN) HESPERIDIN)	450 MG) 50MG)	TABLET	30'S	117,000					
DR0297	DIPHENHYDRAMINE HYDROCHLORIDE) AMMONIUM CHLORIDE) SODIUM CITRATE) ALCOHOL) STRENGTH IS PER 5 ML	14 MG) 36.80 MG) 61.80 MG) 5% W/V)	EXPECTORANT	3.78 L	6,000					
DR0298	DIPHENHYDRAMINE HYDROCHLORIDE*	12.5 MG/5ML	ELIXIR	3.78 L	6,000					
DR0299	DIPHENHYDRAMINE*	25 MG	CAPSULE	1000'S	900					
DR0300	DIPHENHYDRAMINE*	50MG/ML	INJECTION	1 ML	75,000 **					
DR0301	DIPHENOXYLATE ATROPINE	2.5 MG 0.025	TABLET	30'S	270					
DR0302	DIPYRIDAMOLE	75 MG	TABLET	100'S	14,500					
DR0303	DIPYRIDAMOLE	25 MG	TABLET	100'S	11,200					
DR0304	DOBUTAMINE (I.V)*	12.5MG/ML	INJECTION	20 ML	1,500					
DR0305	DOCUSATE SODIUM	100 MG	CAPSULE	30'S	1,500					
DR0306	DOCUSATE SODIUM	12.5 MG/5 ML	SOLUTION	300 ML	600					
DR0307	DOMPERIDONE	5 MG/5 ML	SUSPENSION	200 ML	750					
DR0308	DOMPERIDONE MALEATE	10 MG	TABLET	30'S	3,000					
DR0309	DONEPEZIL	5 MG	TABLET	28'S	108					
DR0310	DONEPEZIL	10 MG	TABLET	28'S	135					
DR0311	DOPAMINE*	40 MG/ML	INJECTION	5 ML	8,100					
DR0312	DORZOLAMIDE	2%	DROPS	5 ML	750					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0313	DORZOLAMIDE) TIMOLOL) (EYE)	2%) 0.5%)	DROPS	5 ML	3,000					
DR0314	DOXORUBICIN (RAPID DISSOLUTION)*	10 MG/VIAL	INJECTION	VIAL	2,250					
DR0315	DOXORUBICIN (RAPID DISSOLUTION)*	50 MG/VIAL	INJECTION	VIAL	9,750					
DR0316	DOXORUBICIN (RAPID DISSOLUTION)*	100 MG/VIAL	INJECTION	VIAL	13,500					
DR0317	DOXYCYCLINE*	100 MG	CAPSULE	100'S	16,200					
DR0318	ECONAZOLE*	1%	CREAM	15 G	27,000					
DR0319	EDROPHONIUM CHLORIDE	10 MG/ML	INJECTION	1 ML	270					
DR0320	EMULSIFYING		OINTMENT	400 G	5,400					
DR0321	EMULSIFYING		WAX	1 KG	540					
DR0322	ENALAPRIL*	5 MG	TABLET	100'S	90,000 **					
DR0323	ENALAPRIL*	10 MG	TABLET	100'S	172,500 **					
DR0324	ENALAPRIL*	20 MG	TABLET	100'S	135,000 **					
DR0325	ENOXAPARIN SODIUM*	40 MG	INJECTION	0.4 ML	1,800					
DR0326	ENOXAPARIN SODIUM*	60 MG	INJECTION	0.6 ML	1,800					
DR0327	ENOXAPARIN SODIUM*	80 MG	INJECTION	0.8 ML	1,800					
DR0328	EPHEDRINE HYDROCHLORIDE		POWDER	25 G	108					
DR0329	EPHEDRINE HYDROCHLORIDE*	30 MG/ML	INJECTION	1 ML	18,000					
DR0330	EPHEDRINE HYDROCHLORIDE*	50 MG/ML	INJECTION	1 ML	2,700					
DR0331	EPOETIN ALFA*	4000 IU	INJECTION	VIAL	16,200					
DR0332	EPOETIN BETA*	4000 IU	INJECTION	VIAL	27,000					
DR0333	ERGOMETRINE MALEATE)	500 MCG)	INJECTION	AMP	27,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
	OXYTOCIN)	5 UNITS)	INJECTION	AMP	27,000					
DR0334	ERYTHROMYCIN ETHYLSUCCINATE*	200 MG/5ML	SUSPENSION	100 ML	25,500					
DR0335	ERYTHROMYCIN STEARATE*	250 MG	TABLET	100'S	8,100					
DR0336	ERYTHROMYCIN STEARATE*	500 MG	TABLET	100'S	5,400					
DR0337	ESMOLOL*	10MG/ML	INJECTION	10 ML	450					
DR0338	ETHAMBUTOL*	400 MG	TABLET	1000'S	162					
DR0339	ETHANOLAMINE OLEATE	5%	INJECTION	2 ML	162					
DR0340	ETOMIDATE (I.V)*	2MG/ML	INJECTION	10 ML	450					
DR0341	ETOPOSIDE	20 MG/ML	INJECTION	5 ML	1,800					
DR0342	EZETIMIBE	10 MG	TABLET	28 'S	517					
DR0343	FACTOR IX FRACTION (DRIED)*		INJECTION	VIAL	90					
DR0344	FACTOR VIII FRACTION, (DRIED)*	298IU	INJECTION	VIAL	120					
DR0345	FELODIPINE	5 MG	TABLET	28'S	1,200					
DR0346	FELODIPINE	10 MG	TABLET	28'S	900					
DR0347	FENTANYL CITRATE	50 MCG/ML	INJECTION	2 ML	28,000 **					
DR0348	FENTANYL CITRATE	50MCG	PATCH	5'S	900					
DR0349	FENTANYL CITRATE	25 MCG	PATCH	5'S	1,500					
DR0350	FENTANYL CITRATE	100 MCG	PATCH	5'S	750					
DR0351	FENTANYL CITRATE	75 MCG	PATCH	5'S	750					
DR0352	FERROUS FUMARATE	200 MG	TABLET	1000'S	1,500					
DR0353	FERROUS SULPHATE THIAMINE)	149.33 MG) 5.0 MG)	SYRUP	120 ML	22,500					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
	RIBOFLAVINE)	2.0 MG)	SYRUP	120 ML	22,500					
	PYRIDOXINE)	1.0 MG)								
	VITAMIN B12)	10.0 MG)								
	NIACINAMIDE)	10.0 MG)								
	PANTHENOL)	0.94 MG)								
	STRENGTH IS PER 5 ML									
DR0354	FERROUS SULPHATE (ORAL)	125MG/ML	DROPS	15 ML	16,200					
DR0355	FERROUS SULPHATE COMPOUND	300 MG	TABLET	1000'S	4,500					
DR0356	FERROUS SULPHATE)	324 MG)	TABLET	1000'S	3,300					
	MIXED LIVER FRACTION)	128 MG)								
	THIAMINE HYDROCHLORIDE)	0.66 MG)								
	RIBOFLAVINE)	0.66 MG)								
	NICOTINAMIDE)	3.33 MG)								
DR0357	FILGRASTIM	300 MCG	INJECTION	0.5 ML	8,700					
DR0358	FINASTERIDE*	5 MG	TABLET	30'S	11,250					
DR0359	FLEET ENEMA*		ENEMA	118 ML	2,700					
DR0360	FLEET PHOSPHO-SODA*		ORAL SOLUTION	45 ML	525					
DR0361	FLUCONAZOLE	200 MG	CAPSULE	4'S	10,500					
DR0362	FLUCONAZOLE	150 MG	CAPSULE	1'S	114,000					
DR0363	FLUDARABINE PHOSPHATE	50 MG	INJECTION	5'S	200					
DR0364	FLUMAZENIL*	100 MCG/ML	INJECTION	5 ML	270					
DR0365	FLUORESCEIN SODIUM (EYE)*	1%	DROPS	0.5 ML	135					
DR0366	FLUORESCEIN SODIUM (EYE)*	2%	DROPS	0.5 ML	1,200					
DR0367	FLUOROURACIL	5%	CREAM	15 G	405					
DR0368	FLUOROURACIL (5-FLUOROURACIL)*	25 MG/ML	INJECTION	10 ML	12,200					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0369	FLUOROURACIL (5-FLUOROURACIL)*	1 G	INJECTION	20 ML	5,000					
DR0370	FLUOXETINE*	20 MG	TABLET	100'S	2,400					
DR0371	FLUPENTHIXOL DECANOATE	20 MG/ML	INJECTION	1 ML	562					
DR0372	FLUPHENAZINE DECANOATE*	25 MG/ML	INJECTION	10 ML	45,000					
DR0373	FLUTAMIDE	250 MG	TABLET	84'S	540					
DR0374	FOLIC ACID*	5 MG	TABLET	500'S	6,000					
DR0375	FORMALDEHYDE	37%	BULK	4 LITRE	1,620					
DR0376	FOSINOPRIL	10 MG	TABLET	30'S	2,400					
DR0377	FOSPHENYTOIN	75MG/ML	INJECTION	1 ML	12,300					
DR0378	FRACTIONATED SOYA OIL)*)* FRACTIONATED OVOLECITHIN) GLYCEROL) (EQUIVALENT TO INTRALIPID 10%)	10%) 1.2%) 2.5%)	INJECTION	250 ML	540					
DR0379	FRACTIONATED SOYA OIL)*)* FRACTIONATED OVOLECITHIN) GLYCEROL) (EQUIVALENT TO INTRALIPID 20%)	20%) 1.2%) 2.5%)	INJECTION	500 ML	540					
DR0380	FRUSEMIDE*	40 MG	TABLET	1000'S	6,900					
DR0381	FRUSEMIDE*	10 MG/ML	INJECTION	2 ML	243,000					
DR0382	FUCIDIN INTERTULLE*		DRESSING	EACH	750					
DR0383	FULLER'S EARTH (BENTONITE)*		BULK		30					
DR0384	FUSIDIC ACID	2%	CREAM	15 G	3,600					
DR0385	GABAPENTIN	100 MG	CAPSULE	100'S	750					
DR0386	GABAPENTIN	300 MG	CAPSULE	100'S	1,050					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0387	GAMMA BENZENE HEXACHLORIDE	1%	CREAM	50 G	12,150					
DR0388	GEMCITABINE	200 MG	INJECTION	VIAL	1,350					
DR0389	GEMCITABINE	1 G	INJECTION	VIAL	1,200					
DR0390	GENTAMICIN (EYE/EAR)*	0.3%	DROPS	5 ML	450					
DR0391	GENTAMICIN SULPHATE*	10 MG/ML	INJECTION	2 ML	54,000					
DR0392	GENTAMICIN SULPHATE*	40 MG/ML	INJECTION	2 ML	120,000 **					
DR0393	GLIBENCLAMIDE*	5 MG	TABLET	500'S	60,000					
DR0394	GLICLAZIDE	80 MG	TABLET	20'S	6,000					
DR0395	GLICLAZIDE MR*	30 MG	TABLET	30'S	125,500					
DR0396	GLICLAZIDE MR*	60 MG	TABLET	30'S	65,400					
DR0397	GLUCAGON*	1 MG/ML	INJECTION	VIAL	165					
DR0398	GLUCOPYROLLATE	0.2 MG/ML	INJECTION	VIAL	75					
DR0399	GLUTARALDEHYDE - (14 DAYS)	2%	BULK	4 L	4,500					
DR0400	GLUTARALDEHYDE - (28 DAYS)	2%	BULK	4 L	5,250					
DR0401	GLYCERIN		BULK	3.8 L	562					
DR0402	GLYCERIN (ADULT)	4 G	SUPPOSITORY	12'S	4,050					
DR0403	GLYCERIN (INFANT)	1 G	SUPPOSITORY	12'S	3,240					
DR0404	GLYCERYL TRINITRATE*	0.6 MG	TABLET	100'S	7,500					
DR0405	GLYCERYL TRINITRATE*	1 MG/ML	INJECTION	5 ML	450					
DR0406	GOSERELIN	3.6 MG	INJECTION	EACH	300					
DR0407	GOSERELIN	10.8 MG	INJECTION	EACH	7,800					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0408	GRANISETRON	3 MG/ML	INJECTION	1 ML	7,500					
DR0409	GRANISETRON	1 MG	TABLET	10'S	1,000					
DR0410	GRISEOFULVIN	125 MG	TABLET	100'S	525					
DR0411	GRISEOFULVIN	125 MG/5 ML	SUSPENSION	120 ML	35,000					
DR0412	GRISEOFULVIN	500 MG	TABLET	1000'S	450					
DR0413	HALOPERIDOL (ORAL)*	1 MG/ML	DROPS	10 ML	300					
DR0414	HALOPERIDOL DECANOATE*	50MG/ML	INJECTION	1 ML	6,000					
DR0415	HALOPERIDOL*	2 MG	TABLET	1000'S	225					
DR0416	HALOPERIDOL*	5 MG	TABLET	1000'S	11,400					
DR0417	HALOPERIDOL*	5 MG/ML	INJECTION	VIAL	50,000					
DR0418	HALOTHANE*		BULK	250 ML	2,250					
DR0419	HEPARIN*	5000 U/ML	INJECTION	5 ML	180,000					
DR0420	HEPATITIS B IMMUNOGLOBULIN (I.M)	0.5 ML	INJECTION	VIAL	60					
DR0421	HUMAN IMMUNOGLOBULIN	6 GM	INJECTION	VIAL	600					
DR0422	HYDRALAZINE HYDROCHLORIDE*	20 MG/ML	INJECTION	1 ML	60,000					
DR0423	HYDRALAZINE HYDROCHLORIDE*	25 MG	TABLET	100'S	27,000					
DR0424	HYDROCHLOROTHIAZIDE*	50 MG	TABLET	1000'S	3,750					
DR0425	HYDROCHLOROTHIAZIDE*	25 MG	TABLET	1000'S	9,000					
DR0426	HYDROCORTISONE		POWDER	100 G	1,350					
DR0427	HYDROCORTISONE (SKIN)*	1%	CREAM	15 G	48,750					
DR0428	HYDROCORTISONE (SKIN)*	1%	OINTMENT	15 G	19,500					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0429	HYDROCORTISONE SKIN	0.5 %	CREAM	15 G	22,500					
DR0430	HYDROCORTISONE SKIN	0.5 %	OINTMENT	15 G	15,000					
DR0431	HYDROCORTISONE SODIUM SUCCINATE*	100 MG/VIAL	INJECTION	VIAL	42,000					
DR0432	HYDROCORTISONE SODIUM SUCCINATE*	250MG/VIAL	INJECTION	VIAL	72,000					
DR0433	HYDROGEN PEROXIDE (20 VOLUME)	6% W/V	SOLUTION	150 ML	48,000					
DR0434	HYDROXOCOBALAMIN*	1000MCG/ML	INJECTION	1 ML	4,500					
DR0435	HYDROXYCHLOROQUINE SULPHATE	200 MG	TABLET	100'S	600					
DR0436	HYDROXYETHYLCELLULOSE (STERILE) (EQUIVALENT TO K.Y.)		JELLY	4 OZ	21,750					
DR0437	HYDROXYUREA*	500 MG	CAPSULE	100'S	1,200					
DR0438	IBUPROFEN	100 MG/5ML	SYRUP	60 ML	1,125					
DR0439	IBUPROFEN*	200 MG	TABLET	1000'S	1,800					
DR0440	IBUPROFEN*	400 MG	TABLET	1000'S	4,500					
DR0441	IBUPROFEN*	600 MG	TABLET	100'S	3,750					
DR0442	ICHTHAMMOL		BULK	100 G	540					
DR0443	IFOSFAMIDE	1 G	INJECTION	VIAL	300					
DR0444	IMIPENEM* CILASTATIN	500 MG 500 MG	INJECTION	VIAL	8,100					
DR0445	IMIPRAMINE	10 MG	TABLET	1000'S	165					
DR0446	IMIPRAMINE	25 MG	TABLET	1000'S	810					
DR0447	INDAPAMIDE S. R.	1.5 MG	TABLET	30'S	70,000					
DR0448	INSULIN GLARGINE*	100 U/ML	INJECTION	10 ML	9,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0449	INSULIN HUMAN (ISOPHANE) MIXED* INSULIN HUMAN (REGULAR)	70 U) 30 U)	INJECTION	10 ML	250,000 **					
DR0450	INSULIN HUMAN (NEUTRAL)* (RECOMBINANT DNA ORIGIN)	100 U/ML	INJECTION	10 ML	45,000					
DR0451	INSULIN HUMAN (REGULAR)* (RECOMBINANT DNA ORIGIN)	100 U/ML	INJECTION	10 ML	30,000					
DR0452	IODINE		CRYSTALS	25 G	270					
DR0453	IOPROMIDE (EQUIV. TO ULTRAVIST 300)	0.623 G/ML	INJECTION	50 ML	5,000					
DR0454	IOPROMIDE (EQUIV. TO ULTRAVIST 300)	0.623G/ML	INJECTION	100 ML	5,000					
DR0455	IPECACUANHA*	7 MG/5 ML	SYRUP	50 ML	54					
DR0456	IPRATROPIUM BROMIDE	20MCG/DOSE	INHALER	200 DOSE	2,700					
DR0457	IPRATROPIUM BROMIDE*	250 MCG/ML	SOLUTION	20 ML	67,500					
DR0458	IRON (AS POLYSACCHARIDE) DROPS) FOLIC ACID) CYANOCOBALAMIN)	8 MG) 1 MG) 2MCG)	DROPS	15 ML	18,000					
DR0459	IRON SUCROSE*	20 MG/ML	INJECTION	5 ML	750					
DR0460	ISOFLURANE*		BULK	250 ML	2,700					
DR0461	ISONIAZID*	100 MG	TABLET	100'S	1,650					
DR0462	ISONIAZID*	300 MG	TABLET	100'S	162					
DR0463	ISOPRENALINE	20 MCG	INJECTION	VIAL	450					
DR0464	ISOSORBIDE DINITRATE*	10 MG	TABLET	100'S	94,500					
DR0465	ISOTRETINOIN	20 MG	CAPSULE	30'S	81					
DR0466	ITRACONAZOLE	100 MG	CAPSULE	15'S	3,300					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0467	KETAMINE*	50 MG/ML	INJECTION	10 ML	4,050					
DR0468	KETANSERIN*	2%	GEL	20 G	3,780					
DR0469	KETOCONAZOLE	200 MG	TABLET	100'S	1,080					
DR0470	KETOCONAZOLE*	2%	CREAM	40 G	15,000					
DR0471	KETOCONAZOLE*	2%	SHAMPOO	100 ML	32,400					
DR0472	KETOTIFEN	1 MG/5ML	ELIXIR	300 ML	600					
DR0473	L-ASPARAGINASE	10,000 U	INJECTION	VIAL	1,350					
DR0474	L-THYROXINE SODIUM*	0.1 MG	TABLET	100'S	9,450					
DR0475	L-THYROXINE SODIUM*	25 MCG	TABLET	100'S	1,200					
DR0476	L-THYROXINE SODIUM*	50 MCG	TABLET	100'S	900					
DR0477	LABETOLOL HYDROCHLORIDE*	5 MG/ML	INJECTION	20 ML	1,620					
DR0478	LACTULOSE	667 MG/ML	SOLUTION	500 ML	1,350					
DR0479	LEUPROLIDE DEPOT	3.75 MG	INJECTION	VIAL	900					
DR0480	LEUPROLIDE DEPOT	11.25 MG	INJECTION	VIAL	1,890					
DR0481	LEVODOPA BENSERAZIDE	200 MG 50 MG	TABLET	30'S	480					
DR0482	LEVODOPA)* CARBIDOPA)	100 MG) 25MG)	TABLET	100'S	400					
DR0483	LEVODOPA)* CARBIDOPA)	250MG) 25 MG)	TABLET	100'S	1,080					
DR0484	LEVOFLOXACIN*	500 MG	INJECTION	VIAL	4,500					
DR0485	LEVOFLOXACIN*	750 MG	INJECTION	VIAL	8,100					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0486	LEVOMEPRMAZINE	6 MG	TABLET	20'S	216					
DR0487	LEVONORGESTREL		IMPLANT	EACH	1,350					
DR0488	LIGNOCAINE HYDROCHLORIDE	2%	GEL	20 G	1,620					
DR0489	LIGNOCAINE HYDROCHLORIDE	2%	PATCH	EACH	750					
DR0490	LIGNOCAINE HYDROCHLORIDE)* ADRENALINE) (FOR DENTAL USE)	2%) 1-100,000)	INJECTION	50 CART.	7,500					
DR0491	LIGNOCAINE HYDROCHLORIDE)* ADRENALINE)	2%) 1-200,000)	INJECTION	20 ML	750					
DR0492	LIGNOCAINE HYDROCHLORIDE*	2%	INJECTION	50 ML	3,000					
DR0493	LIGNOCAINE HYDROCHLORIDE*	2%	INJECTION	20 ML	3,240					
DR0494	LIGNOCAINE HYDROCHLORIDE*	2%	INJECTION	2 ML	490,000	**				
DR0495	LIGNOCAINE HYDROCHLORIDE*	10%	SPRAY	30 ML	300					
DR0496	LIGNOCAINE) EPINEPHRINE)	2%) 1:100,000)	INJECTION	VIAL	120,000					
DR0497	LIQUID PARAFFIN (HEAVY)*		OIL	2 L	300					
DR0498	LIQUID PARAFFIN (LIGHT)*		OIL	2 L	450					
DR0499	LISINOPRIL	5 MG	TABLET	28'S	3,600					
DR0500	LISINOPRIL	10 MG	TABLET	28'S	4,950					
DR0501	LISINOPRIL	20 MG	TABLET	28'S	2,250					
DR0502	LITHIUM CARBONATE*	250 MG	TABLET	100'S	4,050					
DR0503	LOMUSTINE (CCNU)	10 MG	CAPSULE	20'S	90					
DR0504	LOMUSTINE (CCNU)	40 MG	CAPSULE	20'S	60					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0505	LOMUSTINE (CCNU)	100 MG	CAPSULE	20'S	60					
DR0506	LOPERAMIDE HYDROCHLORIDE	2 MG	CAPSULE	100'S	675					
DR0507	LORATIDINE	10 MG	TABLET	20'S	15,000					
DR0508	LORATIDINE	5 MG/ 5ML	SYRUP	100 ML	3,000					
DR0509	LORAZEPAM*	4MG/ML	INJECTION	1 ML	600					
DR0510	LOSARTAN	50 MG	TABLET	20'S	120,000					
DR0511	LOSARTAN	25 MG	TABLET	20'S	60,000					
DR0512	MAGNESIUM SULPHATE		CRYSTALS	1 KG	150					
DR0513	MAGNESIUM SULPHATE*	50%	INJECTION	50 ML	9,000					
DR0514	MANNITOL*	20%	INJECTION	500 ML	4,500					
DR0515	MANNITOL*	10%	INJECTION	500 ML	3,600					
DR0516	MEBENDAZOLE	100 MG	TABLET	6'S	15,000					
DR0517	MEBENDAZOLE**	100 MG/5ML	SUSPENSION	30 ML	12,150					
DR0518	MEDROXYPROGESTERONE ACETATE*	150MG/ML	INJECTION	1 ML	12,000					
DR0519	MEFENAMIC ACID	250 MG	CAPSULE	500'S	1,620					
DR0520	MEFENAMIC ACID	500 MG	CAPSULE	500'S	1,890					
DR0521	MELOXICAM	7.5 MG	TABLET	400'S	500					
DR0522	MELOXICAM	15 MG	TABLET	400'S	1,000					
DR0523	MELPHALAN*	2 MG	TABLET	25'S	540					
DR0524	MENTHOL		CRYSTALS	100 G	195					
DR0525	MERCAPTOPYRINE*	50 MG	TABLET	25'S	1,080					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0526	MEROPENEM	500 MG	INJECTION	VIAL	9,450					
DR0527	MEROPENEM	1 G	INJECTION	VIAL	10,800					
DR0528	METAMIZOL (ORAL)	500 MG/ML	DROPS	10 ML	3,750					
DR0529	METAMIZOL SODIUM	500 MG	TABLET	250'S	20,000					
DR0530	METAMIZOL SODIUM	500 MG/ ML	INJECTION	2 ML	500,000 **					
DR0531	METARAMINOL*	10 MG/ML	INJECTION	VIAL	6,000					
DR0532	METFORMIN HYDROCHLORIDE	850 MG	TABLET	100'S	3,600					
DR0533	METFORMIN HYDROCHLORIDE XR	500 MG	TABLET	100'S	14,550					
DR0534	METFORMIN HYDROCHLORIDE*	500 MG	TABLET	500'S	65,000					
DR0535	METHADONE HYDROCHLORIDE	10MG/ML	INJECTION	1ML	1,620					
DR0536	METHADONE HYDROCHLORIDE	5 MG	TABLET	50'S	162					
DR0537	METHOTREXATE (WITHOUT PRESERVATIVE)*	25 MG/ML	INJECTION	2 ML	2,250 **					
DR0538	METHOTREXATE*	2.5 MG	TABLET	100'S	1,000					
DR0539	METHYL SALICYLATE		BULK	1 L	60					
DR0540	METHYLDOPA*	250 MG	TABLET	500'S	4,950					
DR0541	METHYLDOPA*	500 MG	TABLET	500'S	8,100					
DR0542	METHYLERGONOVINE MALEATE*	200 MCG	TABLET	30'S	675					
DR0543	METHYLERGONOVINE MALEATE*	200 MCG/ML	INJECTION	AMP	45,000					
DR0544	METHYLPHENIDATE HYDROCHLORIDE*	10 MG	TABLET	30'S	81					
DR0545	METHYLPHENIDATE HYDROCHLORIDE*	18 MG	TABLET	30'S	810					
DR0546	METHYLPHENIDATE HYDROCHLORIDE*	27 MG	TABLET	30'S	1,500					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

NATIONAL HEALTH FUND PHARMACEUTICAL DIVISION

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0547	METHYLPHENIDATE HYRDOCHLORIDE*	36 MG	TABLET	30'S	405					
DR0548	METHYLPREDNISOLONE SODIUM SUCCINATE*	500 MG	INJECTION	7.7 ML	8,100					
DR0549	METHYLPREDNISOLONE ACEPONATE*	0.1%	OINTMENT	15 G	4,590					
DR0550	METHYLPREDNISOLONE ACEPONATE*	0.1%	CREAM	15 G	9,450					
DR0551	METHYLPREDNISOLONE ACETATE*	40 MG/ML	INJECTION	5 ML	2,100					
DR0552	METOCLOPRAMIDE HYDROCHLORIDE*	5 MG/5 ML	SYRUP	100 ML	1,125					
DR0553	METOCLOPRAMIDE HYDROCHLORIDE*	10 MG	TABLET	500'S	810					
DR0554	METOCLOPRAMIDE HYDROCHLORIDE*	5 MG/ML	INJECTION	2 ML	50,000					
DR0555	METOLAZONE	5 MG	TABLET	100'S	1,125					
DR0556	METRONIDAZOLE	100 MG	PESSARIES	10'S	54,000					
DR0557	METRONIDAZOLE (ORAL)	200 MG/5ML	SUSPENSION	100 ML	8,100					
DR0558	METRONIDAZOLE*	400 MG	TABLET	100'S	5,400					
DR0559	METRONIDAZOLE*	5 MG/ML	INJECTION	100 ML	260,000					
DR0560	METRONIDAZOLE*	250 MG	TABLET	500'S	5,400					
DR0561	METRONIDAZOLE*	500 MG	CAPSULE	100 'S	16,500					
DR0562	MIDAZOLAM*	7.5 MG	TABLET	100'S	270					
DR0563	MIDAZOLAM*	15 MG	INJECTION	3 ML	13,500					
DR0564	MIDAZOLAM*	5 MG/ML	INJECTION	5 ML	12,000					
DR0565	MIDAZOLAM*	50 MG/10 ML	INJECTION	10 ML	10,000					
DR0566	MILRINONE	1 MG/ML	INJECTION	10 ML	750					
DR0567	MINOXIDIL	2.5 MG	TABLET	100'S	45					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0568	MINOXIDIL	5 MG	TABLET	100'S	90					
DR0569	MINOXIDIL	10 MG	TABLET	100'S	45					
DR0570	MISOPROSTOL	200 MCG	TABLET	60'S	162					
DR0571	MOMETASONE FUROATE NASAL	50 MCG	SPRAY	140 DOSES	4,200					
DR0572	MORPHINE HYDROCHLORIDE		POWDER	25 G	300					
DR0573	MORPHINE SULPHATE (SLOW RELEASE)*	10 MG	TABLET	60'S	540					
DR0574	MORPHINE SULPHATE (SLOW RELEASE)*	30 MG	TABLET	60'S	1,350					
DR0575	MORPHINE SULPHATE (SLOW RELEASE)*	60 MG	TABLET	60'S	1,080					
DR0576	MORPHINE SULPHATE (SLOW RELEASE)*	100 MG	TABLET	60'S	450					
DR0577	MORPHINE SULPHATE*	15 MG/ML	INJECTION	1 ML	24,000					
DR0578	MORPHINE SULPHATE*	10 MG/ML	INJECTION	1 ML	15,000					
DR0579	MUPIROCIN*	2%	OINTMENT	15 G	72,000 **					
DR0580	MUSTINE HYDROCHLORIDE*	10 MG	INJECTION	VIAL	225					
DR0581	MYCOPHENOLATE MOFETIL	500 MG	CAPSULE	100'S	2,160					
DR0582	MYCOPHENOLATE MOFETIL	5 MG/ML	INJECTION	VIAL	300					
DR0583	NALIDIXIC ACID	500 MG	TABLET	500'S	45					
DR0584	NALOXONE HYDROCHLORIDE*	0.4 MG/ML	INJECTION	1 ML	6,000					
DR0585	NALOXONE HYDROCHLORIDE*	0.02 MG/ML	INJECTION	2 ML	3,000					
DR0586	NEOSTIGMINE BROMIDE*	15 MG	TABLET	100'S	225					
DR0587	NEOSTIGMINE METHYLSULPHATE*	0.5 MG/ML	INJECTION	1 ML	4,500					
DR0588	NEOSTIGMINE METHYLSULPHATE*	2.5 MG/ML	INJECTION	1 ML	6,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0589	NEOSTIGMINE*	12.5 MG/ 5 ML	INJECTION	VIAL	5,000					
DR0590	NIFEDIPINE S.R.	20 MG	TABLET	100'S	139,500 **					
DR0591	NIFEDIPINE S.R.	10 MG	TABLET	100'S	82,500 **					
DR0592	NIFEDIPINE S.R.	30 MG	TABLET	30'S	4,050					
DR0593	NITROFURANTOIN	100 MG	TABLET	100'S	540					
DR0594	NORADRENALINE	2 MG/ML	INJECTION	2 ML	2,000					
DR0595	NORFLOXACIN	400 MG	TABLET	14'S	18,900					
DR0596	NYSTATIN	100000 U/ML	SUSPENSION	60 ML	12,000					
DR0597	NYSTATIN VAGINAL(EFFERVESCENT)	100,000 UNITS	TABLET	15'S	2,700					
DR0598	OESTROGENS CONJUGATED	25 MG/VIAL	INJECTION	5 ML	9,000					
DR0599	OESTROGENS CONJUGATED	0.625 MG	TABLET	84'S	900					
DR0600	OESTROGENS CONJUGATED	1.25 MG	TABLET	84'S	1,200					
DR0601	OLANZAPINE	10 MG	TABLET	28'S	5,400					
DR0602	OMEPRAZOLE*	20 MG	CAPSULE	14'S	8,100					
DR0603	OMEPRAZOLE*	40 MG	INJECTION	VIAL	1,500					
DR0604	ONDANSETRON HYDROCHLORIDE	8 MG	TABLET	15'S	900					
DR0605	ONDANSETRON HYDROCHLORIDE	2 MG/ML	INJECTION	2 ML	1,800					
DR0606	ORPHENADRINE CITRATE	50 MG	TABLET	500'S	1,125					
DR0607	OSELTAMIVIR	30 MG	CAPSULE	10'S	75					
DR0608	OSELTAMIVIR	45 MG	CAPSULE	10'S	75					
DR0609	OXALIPLATIN	50 MG	INJECTION	VIAL	1,200					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0610	OXALIPLATIN	100 MG	INJECTION	VIAL	1,000					
DR0611	OXCARBAMAZEPINE	150 MG	TABLET	50'S	450					
DR0612	OXCARBAMAZEPINE	300 MG	TABLET	50'S	486					
DR0613	OXCARBAMAZEPINE	300 MG/ 5 ML	SUSPENSION	250 ML	450					
DR0614	OXYBUTININ HYDROCHLORIDE	2.5 MG	TABLET	56'S	75					
DR0615	OXYBUTININ HYDROCHLORIDE	5 MG	TABLET	56'S	2,700					
DR0616	OXYCODONE HYDROCHLORIDE	10 MG	CAPSULE	56'S	675					
DR0617	OXYCODONE HYDROCHLORIDE	40 MG	CAPSULE	56'S	675					
DR0618	OXYCODONE HYDROCHLORIDE	80 MG	CAPSULE	56'S	450					
DR0619	OXYCODONE HYDROCHLORIDE	10 MG/ML	INJECTION	1 ML	450					
DR0620	OXYMETAZOLINE (NASAL)		SPRAY	10 ML	1,350					
DR0621	OXYTOCIN*	10 UNITS/ML	INJECTION	1 ML	250,000 **					
DR0622	PACLITAXEL	30 MG	INJECTION	VIAL	9,450					
DR0623	PACLITAXEL	300 MG	INJECTION	VIAL	4,800					
DR0624	PANCURONIUM BROMIDE	4 MG/2ML	INJECTION	2 ML	7,000					
DR0625	PANTOPRAZOLE	20 MG	TABLET	28 PK	4,800					
DR0626	PANTOPRAZOLE	40 MG	TABLET	28'S	3,600					
DR0627	PANTOPRAZOLE*	40 MG	INJECTION	VIAL	9,000					
DR0628	PARA-AMINO-SALICYLIC ACID	500 MG	TABLET	500'S	225					
DR0629	PARACETAMOL CODEINE PHOSPHATE	500 MG 30 MG	TABLET	100'S	4,860					
DR0630	PARACETAMOL*	120 MG/5ML	SYRUP	1.89 L	9,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0631	PARACETAMOL*	500 MG	TABLET	1000'S	8,800 **					
DR0632	PARACETAMOL*	125 MG	SUPPOSITORY	10'S	1,125					
DR0633	PARACETAMOL*	250 MG	SUPPOSITORY	10'S	1,125					
DR0634	PARAFFIN (WHITE, SOFT)		OINTMENT	1.6 KG	225					
DR0635	PARALDEHYDE		INJECTION	5 ML	112					
DR0636	PENTAMIDINE	300 MG	INJECTION	VIAL	300					
DR0637	PENTOXIFYLLINE*	400 MG	TABLET	100'S	54,000 **					
DR0638	PERINDOPRIL	5 MG	TABLET	30'S	750					
DR0639	PERINDOPRIL) INDAPAMIDE)	2 MG) 0.625 MG)	TABLET	30'S	9,000					
DR0640	PERITONEAL DIALYSIS SOLUTION WITH DEXTROSE*	1.50%	SOLUTION	2 LITRE	60,000					
DR0641	PERITONEAL DIALYSIS SOLUTION WITH DEXTROSE*	4.25%	SOLUTION	2 LITRE	480					
DR0642	PERITONEAL DIALYSIS SOLUTION WITH DEXTROSE*	2.25%	SOLUTION	2 LITRE	60,000					
DR0643	PETHIDINE HYDROCHLORIDE*	50 MG/ML	INJECTION	1 ML	121,500					
DR0644	PETHIDINE HYDROCHLORIDE*	100 MG/2ML	INJECTION	2 ML	169,000					
DR0645	PETHIDINE HYDROCHLORIDE*	50 MG	TABLET	50'S	1,250					
DR0646	PHENAZOPYRIDINE	100 MG	TABLET	100'S	75					
DR0647	PHENOBARBITONE SODIUM*	60 MG	TABLET	1000'S	450					
DR0648	PHENOBARBITONE SODIUM*	200 MG/ML	INJECTION	1 ML	6,000					
DR0649	PHENOBARBITONE SODIUM*	15MG/ML	ELIXIR	2L	300					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0650	PHENOBARBITONE SODIUM*	30 MG	TABLET	1000'S	1,890					
DR0651	PHENYLEPHRINE HYDROCHLORIDE (1%)	10MG/ML	INJECTION	1 ML	600					
DR0652	PHENYLEPHRINE HYDROCHLORIDE (EYE)	10%	DROPS	10 ML	750					
DR0653	PHENYLEPHRINE HYDROCHLORIDE (EYE)	2.5%	DROPS	5 ML	750					
DR0654	PHENYTOIN SODIUM*	100 MG	CAPSULE	84'S	18,900 **					
DR0655	PHENYTOIN SODIUM*	50 MG/ML	INJECTION	5 ML	72,000					
DR0656	PHENYTOIN SODIUM*	125MG/5ML	SYRUP	250 ML	900					
DR0657	PHYTOMENADIONE	10 MG	TABLET	25'S	54					
DR0658	PHYTOMENADIONE (K1)*	10 MG/ML	INJECTION	1 ML	22,500					
DR0659	PHYTOMENADIONE (K1)*	2 MG/ML	INJECTION	1 ML	60,000					
DR0660	PHYTOMENADIONE (K1)*	1 MG/0.5 ML	INJECTION	0.5 ML	60,000					
DR0661	PILOCARPINE (EYE)*	1%	DROPS	10 ML	225					
DR0662	PILOCARPINE (EYE)*	2%	DROPS	10 ML	2,400					
DR0663	PILOCARPINE (EYE)*	3%	DROPS	10 ML	180					
DR0664	PILOCARPINE (EYE)*	4%	DROPS	10 ML	2,700					
DR0665	PIMECROLIMUS	1%	CREAM	15 G	450					
DR0666	PIOGLITAZONE	15 MG	TABLET	28'S	10,800					
DR0667	PIOGLITAZONE	30 MG	TABLET	28'S	10,800					
DR0668	PIOGLITAZONE	45 MG	TABLET	28'S	45					
DR0669	PIPERACILLIN) TAZOBACTAM)	4 G) 0.5G)	INJECTION	VIAL	15,000					
DR0670	PLASMA SUBSTITUTE (I.V.)*		INJECTION	500 ML	20,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0671	PODOPHYLLUM RESIN		POWDER	100 G	135					
DR0672	POTASSIUM CHLORIDE* (40 MEQ. POTASSIUM/15ML)	20% W/V	INJECTION	20 ML	48,600 **					
DR0673	POTASSIUM CHLORIDE*	600 MG	TABLET	1000'S	2,100					
DR0674	POTASSIUM PERMANGANATE*		CRYSTALS	500 G	270					
DR0675	POVIDONE-IODINE	10%	OINTMENT	15 G	1,350					
DR0676	POVIDONE-IODINE**	10%	SOLUTION	1 LITRE	32,000					
DR0677	PRALIDOXIME MESYLATE*	200 MG/ML	INJECTION	5 ML	540					
DR0678	PRAVASTATIN	10 MG	TABLET	30'S	1,050					
DR0679	PRAVASTATIN	20 MG	TABLET	30'S	900					
DR0680	PREDNISOLONE	15 MG/5ML	SYRUP	60 ML	4,050					
DR0681	PREDNISOLONE RETENTION*	20 MG	ENEMA	100 ML	200					
DR0682	PREDNISOLONE*	5 MG	TABLET	500'S	2,700					
DR0683	PREDNISON*	5 MG	TABLET	1000'S	6,000					
DR0684	PREDNISON*	50 MG	TABLET	100'S	810					
DR0685	PRIMAQUINE	15 MG	TABLET	500'S	225					
DR0686	PROBENECID*	500 MG	TABLET	100'S	150					
DR0687	PROCAINAMIDE	500MG/ML	INJECTION	VIAL	165					
DR0688	PROCAINE PENICILLIN*	3 MEGAUNIT	INJECTION	VIAL	10,800					
DR0689	PROCARBAZINE HYDROCHLORIDE*	50 MG	CAPSULE	50'S	135					
DR0690	PROCHLORPERAZINE MALEATE*	5 MG	TABLET	1000'S	700					
DR0691	PROCHLORPERAZINE MESYLATE*	12.5 MG/ML	INJECTION	1 ML	8,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0692	PROGUANIL HYDROCHLORIDE	100 MG	TABLET	98'S	300					
DR0693	PROGUANIL HYDROCHLORIDE	250 MG	TABLET	98'S	300					
DR0694	PROMETHAZINE HYDROCHLORIDE*	25 MG/ML	INJECTION	2 ML	12,000					
DR0695	PROMETHAZINE HYDROCHLORIDE*	10 MG	TABLET	56'S	45					
DR0696	PROPOFOL*	10MG/ML	INJECTION	20 ML	25,000					
DR0697	PROPRANOLOL HYDROCHLORIDE	10 MG	TABLET	100'S	1,000					
DR0698	PROPRANOLOL HYDROCHLORIDE	40 MG	TABLET	1000'S	400					
DR0699	PROPRANOLOL HYDROCHLORIDE	80 MG	TABLET	100'S	600					
DR0700	PROPRANOLOL HYDROCHLORIDE	1 MG/ML	INJECTION	AMP.	2,000					
DR0701	PROPYLTHIOURACIL*	50 MG	TABLET	100'S	850					
DR0702	PROSTAGLANDIN E1 I.V.*	1MG/ML	INJECTION	1 ML	60					
DR0703	PROTAMINE SULPHATE*	50 MG/ML	INJECTION	10 ML	1,420					
DR0704	PROXYMETACAINE (EYE)	0.5%	DROPS	0.5 ML	600					
DR0705	PSEUDOEPHEDRINE HCL	60 MG	TABLET	24'S	440					
DR0706	PYRAZINAMIDE*	500 MG	TABLET	100'S	1,200					
DR0707	PYRIDOSTIGMINE BROMIDE*	60 MG	TABLET	200'S	540					
DR0708	PYRIDOXINE HYDROCHLORIDE (I.M)		INJECTION	AMP	850					
DR0709	PYRIDOXINE*	50 MG	TABLET	20'S	1,525					
DR0710	PYRIMETHAMINE	25 MG	TABLET	30'S	220					
DR0711	QUETIAPINE	100 MG	TABLET	30'S	3,000					
DR0712	QUETIAPINE	200 MG	TABLET	30'S	1,420					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0713	QUETIAPINE	300 MG	TABLET	30'S	1,400					
DR0714	QUETIAPINE	150 MG	TABLET	30'S	1,940					
DR0715	QUININE SULPHATE	300 MG	INJECTION	VIAL	75					
DR0716	RANITIDINE HYDROCHLORIDE (I.M./I.V.)*	50 MG/ML	INJECTION	2 ML	350,000 **					
DR0717	RANITIDINE HYDROCHLORIDE*	300 MG	TABLET	100'S	18,000					
DR0718	RANITIDINE HYDROCHLORIDE*	75 MG/5 ML	SYRUP	150 ML	1,200					
DR0719	RANITIDINE HYDROCHLORIDE*	150 MG	TABLET	100'S	32,100					
DR0720	REAGENT FOR TESTING GLUCOSE & PROTEIN/URINE (EQUIVALENT TO URISTIX)		STRIPS	50'S	1,000					
DR0721	REAGENT FOR TESTING PROTEIN, KETONES, PH, GLUCOSE IN URINE (EQ. TO LABSTIX)		STRIPS	100'S	12,000					
DR0722	REAGENT FOR TOTAL SCREEN OF URINE		STRIPS	100'S	5,200					
DR0723	REMIFENTANIL	1 MG	INJECTION	VIAL	1,350					
DR0724	RIFABUTIN	300 MG	TABLET	100'S	540					
DR0725	RIFAMPICIN) ISONIAZID)	300 MG) 150 MG)	TABLET	60'S	650					
DR0726	RIFAMPICIN*	300 MG	CAPSULE	100'S	4,800					
DR0727	RIFAMPICIN*	150 MG	CAPSULE	100'S	3,600					
DR0728	RIFAMPICIN*	100 MG/5ML	SYRUP	50 ML	2,250					
DR0729	RISPERIDONE	2 MG	TABLET	20'S	30,000					
DR0730	RISPERIDONE	1 MG	TABLET	20'S	6,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0731	RISPERIDONE CONSTA	25 MG	INJECTION	VIAL	3,000					
DR0732	RISPERIDONE CONSTA	50 MG	INJECTION	VIAL	450					
DR0733	RISPERIDONE CONSTA	37.5 MG	INJECTION	VIAL	1,890					
DR0734	ROPIVACAINE	0.2%	INJECTION	VIAL	150					
DR0735	ROPIVACAINE	0.75%	INJECTION	VIAL	150					
DR0736	ROPIVACAINE	1.0%	INJECTION	VIAL	150					
DR0737	SALBUTAMOL	500 MCG/ML	INJECTION	1 ML	1,800					
DR0738	SALBUTAMOL	2 MG/5ML	SYRUP	120 ML	15,000 **					
DR0739	SALBUTAMOL) GUAIPHENESIN) STRENGTH IS PER 10ML	2 MG) 100 MG)	EXPECTORANT	100 ML	4,000					
DR0740	SALBUTAMOL RESPIRATOR*	5 MG/ML	SOLUTION	15 ML	48,500					
DR0741	SALBUTAMOL*	2 MG	TABLET	1000'S	150					
DR0742	SALBUTAMOL*	4 MG	TABLET	1000'S	300					
DR0743	SALBUTAMOL*	100 MCG/DOSE	INHALER	200 DOSE	155,000					
DR0744	SALMETEROL FLUTICASONE	25 MCG 250 MCG	EVOHALER	120 DOSE	1,200					
DR0745	SALMETEROL FLUTICASONE	25 MCG 125 MCG	EVOHALER	120 DOSE	10,500					
DR0746	SALMETEROL FLUTICASONE	25 MCG 50 MCG	EVOHALER	120 DOSE	3,600					
DR0747	SELENIUM SULPHIDE	2.5 %	SHAMPOO	100 ML	600					
DR0748	SERTRALINE	50 MG	CAPSULE	100'S	540					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0749	SERTRALINE	100 MG	CAPSULE	250	150					
DR0750	SEVOFLUARANE		BULK	250 ML	1,500					
DR0751	SILDENAFIL	100 MG	TABLET	4'S	680					
DR0752	SILVER NITRATE (EYE)*	1%	DROPS	5 ML	750					
DR0753	SILVER NITRATE STICK (LONG APPLICATOR)	95%	STICKS	25 G	2,250					
DR0754	SILVER SULPHADIAZINE*	1%	CREAM	50 G	23,500					
DR0755	SIMVASTATIN	10 MG	TABLET	30'S	62,000					
DR0756	SIMVASTATIN	20 MG	TABLET	30'S	95,000					
DR0757	SIMVASTATIN	40 MG	TABLET	30'S	15,000					
DR0758	SODA LIME		GRANULES	4.5 KG	162					
DR0759	SODIUM BICARBONATE*	8.40%	INJECTION	50 ML	10,000					
DR0760	SODIUM CHLORIDE	0.90%	INJECTION	50 ML	67,500					
DR0761	SODIUM CHLORIDE (I.V.)*	0.90%	INFUSION	500 ML	960,000 **					
DR0762	SODIUM CHLORIDE (I.V.)*	0.45%	INFUSION	500 ML	120,000					
DR0763	SODIUM CHLORIDE (I.V.)*	6%	INFUSION	500 ML	4,500					
DR0764	SODIUM CHLORIDE (I.V.)*	0.90%	INFUSION	1000 ML	48,000					
DR0765	SODIUM CHLORIDE (I.V.)*	3%	INFUSION	500 ML	180					
DR0766	SODIUM CITRATE		POWDER	5 KG	108					
DR0767	SODIUM CLODRONATE I.V.*	30 MG/ML	INJECTION	VIAL	225					
DR0768	SODIUM CLODRONATE*	520 MG	TABLET	60'S	225					
DR0769	SODIUM LACTATE COMPOUND (I.V.)*		INFUSION	500 ML	500,000 **					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
	(HARTMAN'S SOLUTION)		INFUSION	500 ML	500,000 **					
DR0770	SODIUM LACTATE COMPOUND (I.V.)* (HARTMAN'S SOLUTION)		INFUSION	1000 ML	30,000					
DR0771	SODIUM NITROPRUSSIDE	1%	INJECTION	2 ML	675					
DR0772	SODIUM PICOSULPHATE (ORAL)	75 MG/ML	DROPS	15 ML	810					
DR0773	SODIUM POLYSTYRENE SULPHONATE*		POWDER	1 LB	1,500					
DR0774	SODIUM VALPORATE CHRONO*	200 MG	TABLET	100'S	2,800					
DR0775	SODIUM VALPROATE CHRONO*	300 MG	TABLET	100'S	900					
DR0776	SODIUM VALPROATE CHRONO*	500 MG	TABLET	100'S	450					
DR0777	SODIUM VALPROATE*	200 MG/5ML	SYRUP	300 ML	1,164					
DR0778	SPECTINOMYCIN HYDROCHLORIDE	2 G	INJECTION	VIAL	600					
DR0779	SPIRONOLACTONE	25 MG	TABLET	500'S	3,000					
DR0780	STERILE WATER FOR IRRIGATION		SOLUTION	1500 ML	30,000 **					
DR0781	STERILE WATER FOR IRRIGATION		SOLUTION	3000 ML	6,500					
DR0782	STILBOESTROL DIPHOSPHATE	60 MG/ML	INJECTION	5 ML	610					
DR0783	STILBOESTROL DIPHOSPHATE	1 MG	TABLET	100'S	405					
DR0784	STILBOESTROL DIPHOSPHATE	5 MG	TABLET	100'S	405					
DR0785	STREPTOKINASE*	250,000 U	INJECTION	VIAL	120					
DR0786	STREPTOMYCIN SULPHATE*	1 G	INJECTION	VIAL	4,000					
DR0787	SUCRALFATE	1 G	TABLET	112'S	280					
DR0788	SULPHADIAZINE	500 MG	TABLET	56'S	189					
DR0789	SULPHADIAZINE	250 MG	TABLET	56'S	60					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0790	SULPHAMETHOXAZOLE) (PAEDIATRIC)* TRIMETHOPRIM) STRENGTH IS PER 5 ML	200 MG) 40 MG)	SUSPENSION	100 ML	37,800 **					
DR0791	SULPHAMETHOXAZOLE)* TRIMETHOPRIM) STRENGTH IS PER 5 ML	400 MG) 80 MG)	INJECTION	5 ML	9,450					
DR0792	SULPHAMETHOXAZOLE)* TRIMETHOPRIM)	400 MG) 80 MG)	TABLET	1000'S	1,000					
DR0793	SULPHAMETHOXAZOLE)* TRIMETHOPRIM)	800 MG) 160 MG)	TABLET	100'S	1,665					
DR0794	SULPHASALAZINE	500 MG	TABLET	112'S	900					
DR0795	SUXAMETHONIUM CHLORIDE*	50 MG/ML	INJECTION	10 ML	10,800					
DR0796	TAMOXIFEN CITRATE	10 MG	TABLET	60'S	6,750					
DR0797	TAMSULOSIN XL	400 MCG	TABLET	30'S	50,000					
DR0798	TEMOZOLOMIDE	5 MG	CAPSULE	5'S	112					
DR0799	TEMOZOLOMIDE	20 MG	CAPSULE	5'S	112					
DR0800	TEMOZOLOMIDE	100 MG	CAPSULE	5'S	112					
DR0801	TERAZOSIN	5 MG	TABLET	100'S	4,050					
DR0802	TERAZOSIN	1 MG	TABLET	100'S	600					
DR0803	TERAZOSIN	2 MG	TABLET	100'S	4,000					
DR0804	TERAZOSIN	10 MG	TABLET	100'S	600					
DR0805	TERBINAFIN	1%	CREAM	15 G	48,000					
DR0806	TERBINAFIN	250 MG	TABLET	14'S	24,000					
DR0807	TERBINAFIN	125 MG	TABLET	14'S	7,300					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0808	TERBUTALINE SULPHATE	250 MCG/DOSE	INHALER	400 DOSES	1,500					
DR0809	TERBUTALINE SULPHATE	5 MG	TABLET	20'S	225					
DR0810	TERBUTALINE SULPHATE	500 MCG/ML	INJECTION	5 ML	450					
DR0811	TESTOSTERONE ENANTATE	250 MG	INJECTION	1 ML	225					
DR0812	TETANUS ANTITOXIN	50,000 U/VIAL	INJECTION	5 ML	900					
DR0813	TETANUS IMMUNE GLOBULIN (HUMAN)	250 U/ML	INJECTION	1 ML	900					
DR0814	TETANUS TOXOID		INJECTION	5 ML	4,400					
DR0815	TETRACYCLINE (EYE)	1%	OINTMENT	3.5 G	26,000					
DR0816	TETRACYCLINE (SKIN)*	3%	OINTMENT	10 G	68,500					
DR0817	THEOPHYLLINE	125 MG/5 ML	SYRUP	100 ML	2,400					
DR0818	THIAMINE HYDROCHLORIDE)	5 MG)	CAPSULE	500'S	4,000					
	RIBOFLAVINE)	2 MG)								
	PYRIDOXINE)	2 MG)								
	NICOTINAMIDE)	20 MG)								
	CALCIUM PANTOTHENATE)	3 MG)								
DR0819	THIAMINE HYDROCHLORIDE*	100 MG	TABLET	100'S	450					
DR0820	THIAMINE HYDROCHLORIDE*	100 MG	INJECTION	VIAL	300					
DR0821	THIOGUANINE	40 MG	TABLET	25'S	81					
DR0822	THIOPENTONE SODIUM*	0.5 G/AMP.	INJECTION	20 ML	5,400					
DR0823	THIOPENTONE SODIUM*	1 G/AMP.	INJECTION	50 ML	5,400					
DR0824	TIMOLOL MALEATE (EYE)*	0.25%	DROPS	5 ML	270					
DR0825	TIMOLOL MALEATE (EYE)*	0.50%	DROPS	5 ML	45,000					
DR0826	TOLTERODINE SR	4 MG	TABLET	28'S	540					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0827	TOPIRAMATE*	25 MG	TABLET	20'S	1,600					
DR0828	TOPIRAMATE*	100 MG	TABLET	20'S	1,150					
DR0829	TOPIRAMATE*	50 MG	TABLET	20'S	980					
DR0830	TRAMADOL	20 MG/ML	INJECTION	2 ML	300					
DR0831	TRAMADOL	50 MG	CAPSULE	20'S	300					
DR0832	TRAMADOL (ORAL)	100 MG/ML	DROPS	20 ML	450					
DR0833	TRANEXAMIC ACID	100 MG/ML	INJECTION	5 ML	4,000					
DR0834	TRANEXAMIC ACID	500 MG	TABLET	60'S	54					
DR0835	TRAVAPROST (EYE)	0.004%	DROPS	2.5 ML	10,000					
DR0836	TRETINOIN	0.025%	CREAM	60 G	105					
DR0837	TRETINOIN	0.05%	CREAM	60 G	1,500					
DR0838	TRIAMCINOLONE ORABASE	0.1%	GEL	20 G	200					
DR0839	TRIBENOSIDE*	400 MG	CAPSULE	50'S	75					
DR0840	TRIFLUOPERAZINE*	5 MG	TABLET	1000'S	5,400					
DR0841	TRIFLUOPERAZINE*	1 MG	TABLET	1000'S	120					
DR0842	TRIHYPHENIDYL	2 MG	TABLET	500'S	3,600					
DR0843	TRIHYPHENIDYL	5 MG	TABLET	100'S	10,800					
DR0844	TRIMEPRAZINE TARTRATE*	30 MG/5ML	SYRUP	100 ML	150					
DR0845	TRIMETAPHAN CAMSYLATE	50 MG/ML	INJECTION	5 ML	225					
DR0846	TRIMETAZIDINE	20 MG	TABLET	60'S	5,000					
DR0847	TROPICAMIDE (EYE)	1%	DROPS	15 ML	1,080					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0848	UROGRAFIN	76%	SOLUTION	50 ML	4,500					
DR0849	UROGRAFIN	76%	SOLUTION	100 ML	3,750					
DR0850	UROMITEXAN	100MG/ML	INJECTION	4 ML	2,700					
DR0851	VALPROIC ACID*	250 MG	CAPSULE	100'S	8,650					
DR0852	VALPROIC ACID*	250 MG/5ML	SYRUP	480 ML	2,500					
DR0853	VALPROIC ACID*	500 MG	CAPSULE	100'S	750					
DR0854	VALSARTAN	320 MG	TABLET	28'S	810					
DR0855	VALSARTAN	80 MG	TABLET	28'S	810					
DR0856	VALSARTAN	160 MG	TABLET	28'S	1,200					
DR0857	VALSARTAN) HYDROCHLOROTHIAZIDE)	80 MG) 12.5 MG)	TABLET	28'S	4,500					
DR0858	VALSARTAN) HYDROCHLOROTHIAZIDE)	160 MG) 12.5 MG)	TABLET	28'S	6,210					
DR0859	VALSARTAN) HYDROCHLOROTHIAZIDE)	320 MG) 12.5 MG)	TABLET	28'S	2,160					
DR0860	VALSARTAN) HYDROCHLOROTHIAZIDE)	320 MG) 25 MG)	TABLET	28'S	2,430					
DR0861	VALSARTAN) HYDROCHLOROTHIAZIDE)	160 MG) 25 MG)	TABLET	28'S	1,425					
DR0862	VANCOMYCIN	1 G	INJECTION	VIAL	5,000					
DR0863	VANCOMYCIN	500 MG	INJECTION	VIAL	3,300					
DR0864	VASOPRESSIN AQUEOUS*	20 UNITS /ML	SOLUTION	1 ML	1,350					
DR0865	VENLAFAXINE	37.5 MG	TABLET	100'S	560					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0866	VENLAFAXINE XL	75 MG	CAPSULE	100'S	560					
DR0867	VERAPAMIL	80 MG	TABLET	100'S	600					
DR0868	VERAPAMIL*	2.5 MG/ML	INJECTION	2 ML	625					
DR0869	VINBLASTINE SULPHATE	1 MG/ML	INJECTION	10 ML	1,027					
DR0870	VINCRISTINE SULPHATE	5 MG/VIAL	INJECTION	VIAL	1,800					
DR0871	VINCRISTINE SULPHATE*	1 MG/VIAL	INJECTION	VIAL	4,800					
DR0872	VINPOCETINE	10 MG	TABLET	30'S	24,000					
DR0873	VITAMIN A) ASCORBIC ACID) THIAMINE) PYRIDOXINE) NIACINAMIDE) STRENGTH IS PER 5 ML	2,000 U) 60 MG) 1.0 MG) 1.5 MG) 10.0 MG)	SYRUP	150 ML	19,200					
DR0874	VITAMIN A) (ORAL DROPS) VITAMIN D) ASCORBIC ACID) THIAMINE) RIBOFLAVIN) NIACINAMIDE) STRENGTH IS PER 0.5 ML	1,500 U) 400 U) 30 MG) 0.5 MG) 0.8 MG) 7.0 MG)	DROPS	15 ML	22,000					
DR0875	VITAMIN B & C (HIGH POTENCY) (I.M.)		INJECTION	10 PRS.	420					
DR0876	VITAMIN B & C (HIGH POTENCY) (I.V.)		INJECTION	10 PRS.	600					
DR0877	VITAMIN B COMPLEX		INJECTION	10 ML	1,600					
DR0878	VITAMIN B COMPLEX		TABLET	500'S	9,500					
DR0879	WARFARIN	5 MG	TABLET	100'S	6,000					

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED

SCHEDULE OF PHARMACEUTICAL REQUIREMENTS 2011/2013 TENDER

ALL ITEMS MUST COMPLY WITH STANDARDS AS SPECIFIED BY THE B.P. OR U.S.P. (PLEASE SPECIFY STANDARD)

CODE	GENERIC NAME OF DRUG	STRENGTH	DOSAGE FORM	PACKAGE SIZE	ESTIMATED QUANTITY	UNIT COST SEA C.I.F.	TOTAL COST SEA	UNIT COST AIR C.I.F.	TOTAL COST AIR	LEAD TIME (wks.)
DR0880	WARFARIN	1 MG	TABLET	100'S	200					
DR0881	WATER FOR INJECTION*		INJECTION	50 ML	36,500					
DR0882	WATER FOR INJECTION*		INJECTION	500 ML	80,000 **					
DR0883	WATER FOR INJECTION*		INJECTION	5 ML	2,200					
DR0884	WATER FOR INJECTION*		INJECTION	2 ML	2,200					
DR0885	XYLOMETAZOLINE (NASAL)	1%	SPRAY	10 ML	1,200					
DR0886	XYLOMETAZOLINE (NASAL)	0.5%	DROPS	10 ML	4,200					
DR0887	XYLOMETAZOLINE (NASAL)	1%	DROPS	10 ML	2,800					
DR0888	ZINC HYALURON		GEL	15 G	1,800					
DR0889	ZINC OXIDE		POWDER	1 KG	450					
DR0890	ZUCLOPENTHIXOL ACETATE*	50 MG/ML	INJECTION	1 ML	10,000					
DR0891	ZUCLOPENTHIXOL DECANOATE*	200 MG/ML	INJECTION	1 ML	30,000					
DR0892	ZUCLOPENTHIXOL DIHYDROCHLORIDE*	25 MG	TABLET	20'S	75					
DR0893	ZUCLOPENTHIXOL DIHYDROCHLORIDE*	20 MG/ML	DROPS	10 ML	4,050					
DR0894	ZUCLOPENTHIXOL DIHYDROCHLORIDE*	10 MG	TABLET	20'S	120					

GRAND TOTAL SEA: _____

GRAND TOTAL AIR: _____

KEY: * - VITAL ITEM

** - 50% ORDER QUANTITY GUARANTEED